WO2017207372A1 - Bacillus subtilis strain with probiotic activity - Google Patents

Bacillus subtilis strain with probiotic activity Download PDF

Info

Publication number
WO2017207372A1
WO2017207372A1 PCT/EP2017/062497 EP2017062497W WO2017207372A1 WO 2017207372 A1 WO2017207372 A1 WO 2017207372A1 EP 2017062497 W EP2017062497 W EP 2017062497W WO 2017207372 A1 WO2017207372 A1 WO 2017207372A1
Authority
WO
WIPO (PCT)
Prior art keywords
dsm
animals
strain
subtilis strain
preparation
Prior art date
Application number
PCT/EP2017/062497
Other languages
French (fr)
Inventor
Daniel Petri
Stefan Pelzer
Jessica KLEINBÖLTING
Stella Molck
Maike KIPKER
Claudia BORGMEIER
Sandra HERBOLD
Guido Meurer
Rose Whelan
Kiran DORANALLI
Original Assignee
Evonik Degussa Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Degussa Gmbh filed Critical Evonik Degussa Gmbh
Priority to EP17727530.2A priority Critical patent/EP3464558A1/en
Priority to MX2018014476A priority patent/MX2018014476A/en
Priority to BR112018074616-9A priority patent/BR112018074616A2/en
Priority to JP2018562615A priority patent/JP6991162B2/en
Publication of WO2017207372A1 publication Critical patent/WO2017207372A1/en
Priority to ZA2018/08509A priority patent/ZA201808509B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A01N63/22—Bacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F3/00—Biological treatment of water, waste water, or sewage
    • C02F3/34—Biological treatment of water, waste water, or sewage characterised by the microorganisms used
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Definitions

  • Bacillus subtilis strain with probiotic activity The current invention concerns a new B. subtilis strain with strong inhibition of C. perfringens and its use as probiotic.
  • probiotics also called “direct- fed microbials” or “DFM”
  • DFM direct- fed microbials
  • AGPs antibiotic growth promotors
  • the bacteria according to the current invention exhibit many advantageous features. Besides their ability to inhibit growth of C. perfringens, the main commercially relevant pathogen of poultry, they in particular show a very high proliferation rate in presence of bile and help to digest cellulose in a very effective way.
  • Bacillus subtilis DSM 32315 has been identified by screening of naturally occurring isolates. It has been deposited with the DSMZ on May 12, 2016 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure under the Accession Number as mentioned before in the name of Evonik Degussa GmbH.
  • a first subject of the current invention is a Bacillus subtilis strain and/or a preparation of said Bacillus subtilis strain selected from the following group:
  • gyrB sequence with a sequence identity of at least 99.5 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 3;
  • groEL sequence with a sequence identity of at least 99.5 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 5.
  • a further subject of the current invention is a Bacillus subtilis strain or a preparation thereof, in particular a B. subtilis strain with the characteristics as mentioned before, exhibiting at least one, preferably all, of the following characteristics:
  • a 16S rDNA sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 1;
  • this B. subtilis strain exhibits at least one, more preferably all, of the following further characteristics:
  • an rpoB sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 4;
  • groEL sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 5.
  • a particular subject of the current invention is also a Bacillus subtilis strain, exhibiting the following characteristics:
  • this B. subtilis strain exhibits the following further characteristics:
  • strains of the current invention are preferably characterized by at least one, more preferably by all, of the following further features:
  • They are preferably able to grow under anaerobic conditions. Further, they are preferably able to degrade water-insoluble cellulose as well as protein under such anaerobic conditions.
  • They preferably inhibit infectious bacteria, in particular C. perfringens, very effectively.
  • they are preferably characterized by a pathogen clearance of at least 10 mm, more preferably at least 13 mm, in a well diffusion antagonism assay on LBKelly agar plates with respect to C. perfringens type strain ATCC 13124.
  • the spores are preferably viable at low pHs and preferably survive exposure to pHs as low as 4.0, in particular as low as 3.0, preferably as low as 2.0, for at least one hour.
  • strains according to the invention are preferably further characterized by being able to grow in the presence of 0.05 wt.-% acetic acid, 0.05 wt.-% propionic acid and/or 0.2 wt.-% lactic acid.
  • мем ⁇ ран ⁇ are preferably further characterized by a cellulase activity of at least 200 mU/mL, more preferably at least 300 mU/mL, in particular at least 350 mU/mL, above all about 369 mU/mL, and by a xylanase activity of at least 15 mU/mL, more preferably at least 20 mU/mL, in particular at least 25 mU/mL, above all about 33 mU/mL.
  • a cellulase activity of at least 200 mU/mL, more preferably at least 300 mU/mL, in particular at least 350 mU/mL, above all about 369 mU/mL
  • a xylanase activity of at least 15 mU/mL, more preferably at least 20 mU/mL, in particular at least 25 mU/mL, above all about 33 mU/mL.
  • the B. subtilis strains according to the invention are preferably further characterized by being able to grow in presence of 2 mM bile, more preferably in presence of 4 mM bile.
  • they are preferably characterized by an AUC5 performance value of at least 0.5, preferably at least 0.65, above all at least 0.8, in particular about 0.88, and an AUC10 performance value of at least 1.2, preferably at least 1.4, above all at least 1.6, in particular about 1.7, in presence of 2 mM bile, respectively.
  • the strains are preferably able to grow under high salt conditions, in particular in presence of 5 wt.-% of NaCl, for at least one day.
  • the strains of the current invention preferably survive the high temperatures necessary for pelleting animal feed, in particular they preferably survive a temperature of 80°C for at least 20 minutes.
  • Bacillus subtilis strains according to the current invention enhance animal health by a multifaceted mode of action, including the production of antibacterial metabolites with selective efficacy and the competition with pathogenic bacteria by better consuming the available nutrients, thereby suppressing effective establishment of pathogenic bacteria in the gut.
  • probiotics in comparison to antibiotics, that they do not destroy bacteria indiscriminately nor do they lead to antibiotic resistant strains of pathogenic bacteria. Normally they are able to selectively compete with pathogenic bacteria by production of antimicrobial substances with specific efficacy, and are ideally able to simultaneously enhance the growth and viability of beneficial gut microflora. Further, they are preferably able to stimulate a systemic immune response in the treated animals.
  • the mutant strains of DSM 32315 of the current invention are preferably spontaneous mutants.
  • spontaneous mutant refers to mutants that arise from DSM 32315 without the intentional use of mutagens.
  • Such spontaneous mutants may be obtained by classical methods, such as growing the Bacillus subtilis strain in the presence of UV light or in the presence of a certain antibiotic to which the parent is susceptible and testing any resistant mutants for improved biological activity or improved ability to enhance one or more of the indicia of animal health. Other methods for identifying spontaneous mutants are known to those of ordinary skill in the art. But besides these preferred spontaneous mutants all other kinds of mutants of DSM 32315, like mutants obtained by genetic engineering, are also comprised by the current invention.
  • One particular embodiment of the current invention are naturally non-occurring mutants of the strain DSM 32315 characterized by the features as mentioned before.
  • the strains and preparations of the present invention are preferably administered orally to animals or human beings.
  • a further subject of the current invention are compositions, such as feedstuffs, foodstuffs, drinking and rearing water as well as therapeutic compositions, containing a B. subtilis strain and/or a preparation of the current invention.
  • a further subject of the current invention is also the use of a B. subtilis strain and/or a preparation of the current invention as a probiotic ingredient (DFM) in feed or food products.
  • DFM probiotic ingredient
  • Preferred foodstuffs according to the invention are dairy products, in particular yoghurt, cheese, milk, butter and quark.
  • the cells of the strains of the current invention may be present, in particular in the compositions of the current invention, as spores (which are dormant), as vegetative cells (which are growing), as transition state cells (which are transitioning from growth phase to sporulation phase) or as a combination of at least two, in particular all of these types of cells.
  • the composition of the current invention comprises mainly or only spores.
  • Bacillus subtilis strains of the current invention and compositions containing them when administered to animals, preferably enhance the health of such animals and/or improve the general physical condition of such animals and/or improve the feed conversion rate of such animals and/or decrease the mortality rate of such animals and/or increase the survival rates of such animals and/or improve the weight gain of such animals and/or increase the productivity of such animals and/or increase the disease resistance of such animals and/or increase the immune response of such animals and/or establish or maintain a healthy gut microflora in such animals and/or reduce the pathogen shedding through the feces of such animals.
  • the strains and compositions of the current invention might be used to assist in re-establishing a healthy balance of the gut microflora after administration of antibiotics for therapeutic purposes.
  • a further subject of the current invention is therefore a method of enhancing the health of animals and/or of improving the general physical condition of animals and/or of improving the feed conversion rate of animals and/or of decreasing the mortality rate of animals and/or of increasing the survival rates of animals and/or of improving the weight gain of animals and/or of increasing the productivity of animals and/or of increasing the disease resistance of animals and/or of increasing the immune response of animals and/or of establishing or maintaining a healthy gut microflora in animals and/or of reducing the pathogen shedding through the feces of animals, wherein the strains and/or preparations of the current invention or the compositions of the current invention, which comprise such strain(s), are administered to animals.
  • a further subject of the current invention is therefore also the use of strains and/or preparations and/or compositions of the current invention for enhancing the health of animals and/or for improving the general physical condition of animals and/or for improving the feed conversion rate of animals and/or for decreasing the mortality rate of animals and/or for increasing the survival rates of animals and/or for improving the weight gain of animals and/or for increasing the productivity of animals and/or for increasing the disease resistance of animals and/or for increasing the immune response of animals and/or for establishing or maintaining a healthy gut microflora in animals and/or for reducing the pathogen shedding through the feces of animals, wherein the strains and/or preparations of the current invention or the compositions of the current invention, which comprise such strain(s), are administered to animals.
  • a further subject of the current invention are therefore also the strains and preparations of the current invention as mentioned before and the compositions of the current invention, containing those strains, for enhancing the health of animals and/or for improving the general physical condition of animals and/or for improving the feed conversion rate of animals and/or for decreasing the mortality rate of animals and/or for increasing the survival rate of animals and/or for improving the weight gain of animals and/or for increasing the productivity of animals and/or for increasing the disease resistance of animals and/or for increasing the immune response of animals and/or for establishing or maintaining a healthy gut microflora in animals and/or for reducing the pathogen shedding through the feces of animals.
  • Increasing the productivity of animals refers in particular to any of the following: production of more or higher quality eggs, milk or meat or increased production of weaned offspring.
  • the methods and uses of the strains, preparations and compositions of the current invention can be therapeutic or non-therapeutic.
  • the methods and uses are non-pharmaceutic, in particular feeding applications.
  • a further subject of the current invention is a method of controlling and/or avoiding detrimental environmental effects of manure or contaminated liquids, the method comprising the step of applying to manure, contaminated liquids, litter, a pit, or a manure pond at least one strain, one preparation and/or one composition according to the current invention.
  • composition is applied in liquid form, for example by spraying, or as a powder, for example by strewing.
  • a further subject of the current invention is a method of controlling and/or improving the consistency of litter, in particular a method of ensuring a solid consistency of litter and/or a method of avoiding foot pad lesions, the method comprising the step of feeding animals, in particular poultry, with at least one strain, one preparation and/or one composition according to the current invention.
  • the strains and preparations according to the invention can also be used for improving the quality of water.
  • a further subject of the current invention is therefore also a method of controlling and/or improving the quality of water or aqueous solutions, in particular of drinking water and/or rearing water, comprising the step of applying to water or an aqueous solution at least one strain and/or at least one preparation and/or at least one composition of the current invention.
  • strains and preparations according to the invention can also be used for treating microbial diseases of plants.
  • a further subject of the current invention is therefore also a method of treating and/or preventing microbial diseases of plants, in particular of cultivated plants, comprising the step of applying to the plants at least one strain and/or at least one preparation and/or at least one composition of the current invention.
  • the application may be carried out in liquid form, such as by spraying, or in solid form, in particular as a powder.
  • an improvement of at least one of the features as mentioned before is realized, wherein realization of the feature preferably means an improvement of at least 1 %, more preferably of at least 3 or at least 5 %, in comparison to an adequate negative control.
  • realization of the feature preferably means an improvement of at least 1 %, more preferably of at least 3 or at least 5 %, in comparison to an adequate negative control.
  • negative control averages known in the animal husbandry field may be used, but preferably as negative control animals which are subjected to the same treatment like the animals tested are used, but without administration of the strains and/or preparations of the current invention.
  • the strains, preparations and compositions of the current invention may be administered or fed to an animal in an amount effective to inhibit and/or decrease the growth of pathogenic bacteria in the animal gut.
  • pathogenic bacteria include Clostridia, Listeria, Salmonella, Enterococci, Staphylococci, Aeromonas, Streptococci, Campylobacter, Escherichia coli, and Vibrio.
  • the methods of the present invention may be used to decrease the amount of pathogenic bacteria shed in animal feces.
  • the methods of the present invention may also be used to maintain or increase the growth of beneficial bacteria, such as lactic acid bacteria, in the animal gut. By decreasing pathogenic bacteria and/or increasing or maintaining beneficial bacteria, the compositions of the present invention are able to maintain an overall healthy gut microflora.
  • a further subject of the current invention is a method of inhibiting and/or decreasing the growth of harmful or pathogenic bacteria and/or maintaining and/or increasing the growth of beneficial bacteria in an animal gut, wherein strains and/or preparations and/or compositions of the current invention are administered to animals and wherein the pathogenic bacteria are preferably selected from Clostridia, in particular C. perfringens and C. difficile, Listeria, in particular L. monocytogenes, L. seeligeri and L. welshimeri, Salmonella, in particular S. enterica, S. gallinarum, S. pullorum, S. arizonae, S.
  • the beneficial bacteria are preferably selected from lactic acid bacteria, in particular from Lactobacilli, and Bifidobacteria.
  • the amount of at least one pathogenic bacterium, in particular the amount of C. perfringens is reduced by at least 0.5 log, more preferably by at least 1 log, 2 log, or 3 log.
  • a further subject of the current invention are also the strains, preparations and compositions of the current invention for inhibiting and/or decreasing the growth of pathogenic bacteria and/or for maintaining and/or increasing the growth of beneficial bacteria in an animal gut, wherein the pathogenic bacteria are preferably selected from Clostridia, in particular C. perfringens and C. difficile, Listeria, in particular L. monocytogenes, L. seeligeri and L. welshimeri, Salmonella, in particular S. enterica, S. gallinarum, S.
  • the beneficial bacteria are preferably selected from lactic acid bacteria, in particular from Lactobacilli, and Bifidobacteria.
  • the occurrence and/or increased growth of the pathogenic bacteria does or can lead to the outbreak of certain diseases.
  • the occurrence and/or increased growth of Clostridium perfringens can lead to the outbreak of gut diseases, in particular to the outbreak of necrotic enteritis in poultry.
  • the occurrence and/or increased growth of Clostridium perfringens can also lead to the outbreak of further diseases like bacterial enteritis, gangrenous dermatitis and colangiohepatitis. Even the mildest form of infection by C. perfringens can already be accompanied by diarrhea, which results in wet litter and by that may lead to secondary diseases like foot pad dermatitis.
  • a further subject of the current invention is therefore also a therapeutic composition comprising the strains and/or compositions of the current invention as mentioned before.
  • a preferred subject in this context is therefore a therapeutic composition for treatment and/or prevention of necrotic enteritis, in particular sub-clinical necrotic enteritis, in animals, preferably poultry, comprising the strains and/or compositions of the current invention as mentioned before.
  • Another preferred subject in this context is therefore a therapeutic composition for treatment and/or prevention of bacterial enteritis, gangrenous dermatitis, colangiohepatitis, clostridiosis, diarrhea and/or foot pad dermatitis, in animals, preferably poultry, comprising the strains and/or compositions of the current invention as mentioned before.
  • a further subject of the current invention is therefore also the treatment and/or prevention of a disease, in particular of a gut disease, preferably of necrotic enteritis, in particular of sub-clinical necrotic enteritis, in poultry, wherein a strain and/or composition and/or preparation of the current invention is administered to an animal in need thereof.
  • a further subject of the current invention is therefore also the treatment and/or prevention of a disease, preferably a disease of poultry, selected from bacterial enteritis, gangrenous dermatitis,
  • colangiohepatitis colangiohepatitis, clostridiosis, diarrhea and/or foot pad dermatitis, wherein a strain and/or composition and/or preparation of the current invention is administered to an animal in need thereof.
  • strains and/or preparations and/or compositions of the current invention can be administered to animals in feed and/or drinking water over multiple days throughout the animal's life or during particular stages or portions of the animal's life.
  • the strains and/or compositions can be administered only in a starter diet or only in a finisher diet of farm animals.
  • a particular subject of the current invention is also a method of enhancing the health of human beings and/or of improving the general physical condition of human beings and/or of increasing the disease resistance of human beings and/or of increasing the immune response of human beings and/or of establishing or maintaining a healthy gut microflora in human beings, wherein the strains and/or preparations of the current invention or the compositions of the current invention, which comprise such strain(s), are administered to human beings.
  • a further subject of the current invention is therefore also the use of strains and/or preparations and/or compositions of the current invention for enhancing the health of human beings and/or for improving the general physical condition of human beings and/or for increasing the disease resistance of human beings and/or for increasing the immune response of human beings and/or for establishing or maintaining a healthy gut microflora in human beings, wherein the strains and/or preparations of the current invention or the compositions of the current invention, which comprise such strain(s), are administered to human beings.
  • compositions of the present invention in particular the feed, food and pharmaceutical compositions as well as the drinking or rearing water, preferably comprise the strains of the current invention and are administered to animals at a rate of about lxlO 3 to about 2x10 12 CFU/g feed or ml water, in particular in a rate of about lxlO 3 or about lxlO 4 or about lxlO 5 or about lxlO 6 or about lxlO 7 or about lxlO 8 or about lxlO 9 or about lxlO 10 or about lxlO 11 or about lxlO 12 CFU/g feed or ml water, preferably in an amount of about lxlO 4 to about lxlO 10 CFU/g feed or ml water, more preferably in an amount of lxl 0 4 to lxlO 7 CFU/g feed or ml water.
  • preferred amounts of the strains and/or preparations of the current invention in the feed, food and water compositions of the current invention range preferably from 0.1 wt.-% to 10 w - %, more preferably from 0.2 wt.-% to 5 wt.-%, in particular from 0.3 wt.-% to 3 wt.-%.
  • the methods of the present invention may be used for all kind of animals, in particular all kind of non- human and non-insect animals, more preferably all kind of vertebrates such as mammals, aquatic animals and birds.
  • Animals that may benefit from the current invention include but are not limited to farm animals, pets, exotic animals, zoo animals, aquatic animals, animals used for sports, recreation or work.
  • Pets are preferably selected from dogs, cats, domestic birds and domestic exotic animals.
  • Aquatic animals are preferably selected from finfish and crustaceans which are preferably intended for human nutrition. These include, in particular, carp, tilapia, catfish, tuna, salmon, trout, barramundi, bream, perch, cod, shrimps, lobster, crabs, prawns and crayfish.
  • Preferred types of salmon in this context are the Atlantic salmon, red salmon, masu salmon, king salmon, keta salmon, coho salmon, Danube salmon, Pacific salmon and pink salmon.
  • Further preferred aquatic animals are fanning fish which are subsequently processed to give fish meal or fish oil. In this connection, the fish are preferably herring, pollack, menhaden, anchovies, capelin or cod.
  • the animals are farm animals, which are raised for consumption or as food-producers, such as poultry, swine and ruminants.
  • the poultry may be selected from productive or domestic poultry, but also from fancy poultry or wild fowl.
  • Preferred productive poultry in this context are chickens, turkeys, ducks and geese.
  • the productive livestock in this context is preferably poultry optimized for producing young stock or poultry optimized for bearing meat.
  • Preferred fancy poultry or wild fowl are peacocks, pheasants, partridges, chukkars, guinea fowl, quails, capercaillies, grouse, pigeons and swans, with quails being especially preferred.
  • Ruminants according to the current invention are preferably selected from cattle, goat and sheep.
  • the compositions of this invention may be fed to preruminants to enhance their health and, in particular, to decrease the incidence of diarrhea in these animals.
  • Preruminants are ruminants, including calves, ranging in age from birth to about twelve weeks.
  • compositions of the current invention may comprise at least one carrier or typical feed ingredients or combinations thereof.
  • Suitable carriers are inert formulation ingredients added to improve recovery, efficacy, or physical properties and/or to aid in packaging and administration. Such carriers may be added individually or in combination. These carriers may be selected from anti-caking agents, anti-oxidation agents, bulking agents, and/or protectants.
  • useful carriers include polysaccharides (in particular starches, maltodextrins, methylcelluloses, gums, chitosan and/or inulins), protein sources (in particular skim-milk powder and/or sweet- whey powder), peptides, sugars (in particular lactose, trehalose, sucrose and/or dextrose), lipids (in particular lecithin, vegetable oils and/or mineral oils), salts (in particular sodium chloride, sodium carbonate, calcium carbonate, chalk, limestone, magnesium carbonate, sodium phosphate, calcium phosphate, magnesium phosphate and/or sodium citrate), and silicates (in particular clays, in particular beolite clay, amorphous silica, fumed/precipitated silicas, zeolites, Fuller's earth, baylith, clintpolite, montmorillonite, diatomaceous earth, talc, bentonites, and/or silicate salts like aluminium, magnesium and/or calcium silicate
  • Suitable carriers for animal feed additives are set forth in the American Feed Control Officials, Inc.' s Official Publication, which publishes annually. See, for example Official Publication of American Feed Control Officials, Sharon Krebs, editor, 2006 edition, ISBN 1-878341-18-9.
  • the carriers can be added after concentrating the fermentation broth and/or during and/or after drying.
  • Preferred carriers according to the invention are selected from calcium carbonate, diatomaceous earth and vegetable oil.
  • a preferred embodiment of the current invention are concentrate compositions, in particular feed additive compositions, i.e. compositions suitable for preparing a feed composition, which comprise at least one strain of the current invention and at least one carrier as mentioned before, wherein the at least one strain is preferably comprised in an amount of 0.1 to 10 wt.-%, more preferably in an amount of 0.2 to 5 wt.-%, in particular in an amount of 0.3 to 3 wt.-%, above all in an amount of 0.4 to 2.2 wt.-%, and the at least one carrier is preferably comprised in an amount of at least 90 wt.-%, preferably in an amount of 90 to 99.9 wt.-%, more preferably in an amount of 95 to 99.8 wt.-%, in particular in an amount of 97 to 99.7 wt.-%, above all in an amount of 97.8 to 99.6 wt.-%, and wherein the carrier consists preferably substantially of limestone, in particular of limestone with
  • compositions of the current invention which contain stabilized strains, can be used for the preparation of feed and pharmaceutical compositions as well as drinking and rearing water which preferably comprise the strains according to the invention in an amount as mentioned in the specification above.
  • 200 to 1000 grams of such a concentrate composition in particular 250, 500 or 1000 grams of such a concentrate composition, are used per ton of feed, drinking or rearing water to provide compositions which can be used for feeding animals.
  • These concentrate compositions preferably comprise at least one strain of the current invention in an amount of lxlO 9 to 2xlO u CFU, in particular 2xl0 9 to lxlO 11 CFU, per g of the concentrate composition.
  • feed and food compositions can be prepared by mixing the concentrate compositions with typical feed or food ingredients, respectively.
  • Suitable typical animal feed ingredients which may be contained in the compositions according to the invention and/or used in the preparation of feed compositions starting from concentrate compositions according to the invention include one or more of the following: proteins, carbohydrates, fats, further probiotics, prebiotics, enzymes, vitamins, immune modulators, milk replacers, minerals, amino acids, coccidiostats, acid-based products and/or medicines, such as antibiotics.
  • Carbohydrates containing components which may be used according to the invention are for example forage, roughage, wheat meal, sunflower meal or soya meal, and mixtures thereof.
  • Proteins containing components which may be used according to the invention are for example soya protein, pea protein, wheat gluten or corn gluten, and mixtures thereof.
  • Fats containing components which may be used according to the invention are in particular oils, of both animal and plant origin, like vegetable oils, for example soya bean oil, rapeseed oil, sunflower seed oil, flaxseed oil or palm oil, fish oil, and mixtures thereof.
  • Proteins containing components which additionally contain fats which may be used according to the invention are for example fish meal, krill meal, bivalve meal, squid meal or shrimp shells, as well as combinations thereof.
  • DMF Further probiotics
  • bacteria selected from the species Bacillus subtilis, Bacillus licheniformis, Bacillus lentus, Bacillus pumilus, Bacillus laterosporus, Bacillus coagulans, Bacillus alevi, Bacillus cereus, Bacillus badius, Bacillus thurigiensis, Enterococcus faecium, and
  • Pediococcus acidilactici Preferred examples are Bacillus licheniformis DSM 32314 (as deposited with the DSMZ on May 12, 2016 under the provisions of the Budapest Treaty on the International
  • Bacillus subtilis PB6 (as described in US Patent No. 7,247,299 and deposited as ATCC Accession No. PTA-6737), which is sold by Kemin under the trademark CLOSTAT®, Bacillus subtilis C-3102 (as described in US Patent No. 4,919,936 and deposited as FERM BP- 1096 with the
  • non-Bacillus probiotics such as Saccharomyces cerevisiae, Pichia pastoris, Aspergillus niger, Aspergillus oryzae, or Hansenula
  • further probiotics which are known to be useful to the human health may be used such as lactic acid producing bacteria, in particular lactobacilli, or Bifidobacteria. If said further probiotics are not formulated as part of the compositions of the present invention, they may be administered together (either at the same time or at different times) with the compositions of the present invention.
  • Prebiotics which may be used according to the invention are preferably oligosaccharides, in particular selected from galactooligosaccharides, silayloligosaccharides, lactulose, lactosucrose,
  • fructooligosaccharides palatinose or isomaltose oligosaccharides, glycosyl sucrose,
  • maltooligosaccharides isomaltooligosaccharides, cyclodextrins, gentiooligosaccharides, soybean oligosaccharides, xylooligosaccharides, dextrans, pectins, polygalacturonan, rhamnogalacturonan, mannan, hemicellulose, arabinogalactan, arabinan, arabinoxylan, resistant starch, mehbiose, chitosan, agarose, inulin, tagatose, polydextrose, and alginate.
  • Enzymes which may be used in feed compositions according to the invention and which may aid in the digestion of feed are preferably selected from phytases (EC 3.1 .3.8 or 3.1.3.26), xylanases (EC
  • galactanases EC 3.2.1 .89
  • galactosidases in particular alpha-galactosidases (EC 3.2.1.22)
  • proteases EC 3.4
  • phospholipases in particular phospholipases Al (EC 3.1 .1.32), A2 (EC 3.1.1.4), C (EC 3.1.4.3), and D (EC 3.1.4.4), lysophospholipases (EC 3.1 .1.5), amylases, in particular alpha- amylases (EC 3.2.1.1 ); lysozymes (EC 3.2.1 .17), glucanases, in particular beta-glucanases (EC 3.2.1.4 or EC 3.2.1.6), glucoamylases, cellulases, pectinases, or any mixture thereof.
  • phytases examples include Bio-FeedTM Phytase (Novozymes), Ronozyme® P and HiPhosTM (DSM Nutritional Products), NatuphosTM (BASF), Finase® and Quantum® Blue (AB Enzymes), the Phyzyme® XP (Verenium/DuPont) and Axtra® PHY (DuPont).
  • Other preferred phytases include those described in e.g. WO 98/28408, WO 00/43503, and WO 03/066847.
  • Examples of commercially available xylanases include Ronozyme® WX and G2 (DSM Nutritional Products), Econase® XT and Barley (AB Vista), Xylathin® (Verenium) and Axtra® XB (Xylanase/beta-glucanase, DuPont). Examples of commercially available proteases include Ronozyme® Pro Act (DSM Nutritional Products).
  • Vitamins which may be used according to the invention are for example vitamin A, vitamin D3, vitamin E, vitamin K, e.g., vitamin K3, vitamin B 12, biotin, choline, vitamin B 1 , vitamin B2, vitamin B6, niacin, folic acid and panthothenate, e.g. , Ca-D-panthothenate, or combinations thereof.
  • Immmune modulators which may be used are for example antibodies, cytokines, spray-dried plasma, interleukins, or interferons, or combinations thereof.
  • Minerals which may be used according to the invention are for example boron, cobalt, chloride, chromium, copper, fluoride, iodine, iron, manganese, molybdenum, selenium, zinc, calcium, magnesium, potassium, or sodium, or combinations thereof.
  • Amino acids which may be used according to the invention are for example lysine, alanine, threonine, methionine or tryptophan, or combinations thereof.
  • a further embodiment of the current invention is a method of preparing an animal feed composition
  • a method of preparing an animal feed composition comprising mixing at least one strain and/or at least one preparation and/or at least one concentrate composition of the current invention, in particular in an amount effective to enhance animal health, with feed ingredients, such as proteins, lipids and/or carbohydrates, and optionally further beneficial substances, preferably as mentioned before, to provide a feeding product.
  • feed ingredients such as proteins, lipids and/or carbohydrates, and optionally further beneficial substances, preferably as mentioned before, to provide a feeding product.
  • This method may comprise for example also a pelleting step.
  • Standard pelleting processes known to those of skill in the art may be used, including extrusion processing of dry or semi-moist feeds.
  • Preferred pelleting temperatures are between about 65° C and about 120° C.
  • the strains and compositions of the present invention can be obtained by culturing the strains of the current invention according to methods well known in the art, including by using the media and other methods as described for example in US 6,060,051, EP0287699 or US2014/0010792.
  • Conventional large-scale microbial culture processes include submerged fermentation, solid state fermentation, or liquid surface culture. Towards the end of fermentation, as nutrients are depleted, the cells of the strains begin the transition from growth phase to sporulation phase, such that the final product of fermentation is largely spores, metabolites and residual fermentation medium. Sporulation is part of the natural life cycle of these strains and is generally initiated by the cell in response to nutrient limitation.
  • Fermentation is configured to obtain high levels of colony forming units of the Bacillus subtilis cells and to promote sporulation.
  • the bacterial cells, spores and metabolites in culture media resulting from fermentation may be used directly or concentrated by conventional industrial methods, such as centrifugation, tangential-flow filtration, depth filtration, and evaporation.
  • the concentrated fermentation broth may be washed, for example via a diafiltration process, to remove residual fermentation broth and metabolites.
  • the fermentation broth or broth concentrate can be dried with or without the addition of carriers using conventional drying processes or methods such as spray drying, freeze drying, tray drying, fluidized-bed drying, drum drying, or evaporation.
  • the resulting dry products may be further processed, such as by milling or granulation, to achieve a specific particle size or physical format. Carriers, as described above, may also be added post-drying.
  • Preparations of the strains of the current invention may be cell-free preparations or preparations containing cell debris or preparations containing a mixture of intact cells and cell debris.
  • Cell-free preparations of the strains of the current invention can be obtained for example by centrifugation and/or filtration of fermentation broth. Depending on the technique used, these cell- free preparations may not be completely devoid of cells, but may still comprise a smaller amount of cells.
  • the supernatant of the cells comprises a mixture of such compounds, in particular metabolites, enyzmes and/or peptides, as secreted by the cells.
  • the preparation of the strains is a supernatant of the fermentation broth.
  • compositions comprising cell debris of the strains may be obtained by rupturing the cells applying techniques as known to those of skill in the art, for example by mechanical means or by applying high pressure. Depending on the degree of force applied, a composition comprising only ruptured cells or a composition comprising a mixture of cell debris and intact cells is obtained. Homogenization of the cells may be realized for example by utilizing a French cell press, sonicator, homogenizer,
  • Cell-free preparations of the current invention comprise also preparations which are obtained by first rupturing the cells by applying techniques as mentioned before and subsequently removing the cell debris and the remaining intact cells. Removing of the cell debris and remaining intact cells can be carried out in particular by centrifugation and/or filtration.
  • the preparations of the strains of the current invention may comprise as active compounds at least one metabolite, preferably a mixture of metabolites, as further described below, and/or at least one enzyme selected from proteases, in particular subtilisin, xylanases and/or cellulases, and/or at least one peptide, and/or combinations thereof.
  • a preparation containing an effective mixture of metabolites as contained in the strains of the current invention and/or as contained in the cell preparations as mentioned before, can be obtained for example according to the methods set forth in US Patent No. 6,060,051.
  • the preparation can be obtained by precipitating the metabolites as contained in the preparations mentioned before by using organic solvents like ethyl acetate and subsequent redissolving of the precipitated metabolites in an appropriate solvent.
  • the metabolites may subsequently be purified by size exclusion filtration that groups metabolites into different fractions based on molecular weight cut-off.
  • the preparation containing an effective mixture of metabolites of the current invention preferably comprises at least five, more preferably at least 6, 7, 8, 9, 10 or 12, in particular all metabolites of the strains of the invention.
  • the content of metabolites of the strain DSM 32315 is depicted in Table 5.1.
  • the metabolites possess preferably a molecular weight of between 400 and 4000 Dalton, more preferably of between 500 and 3500 Dalton.
  • an effective amount of the strains and/or preparations and/or compositions of the current invention is used in the embodiments of the current invention.
  • effective amount refers to an amount which effects at least one beneficial effect to an animal and/or to the environment, in particular with respect to the features as already mentioned before, in comparison to an animal that has not been administered the strains and/or preparations and/or compositions of the current invention, but besides that has been administered the same diet (including feed and other compounds).
  • a therapeutic amount of the strains and/or preparations and/or compositions of the current invention is used.
  • the term "therapeutic amount” refers to an amount sufficient to ameliorate, reverse or prevent a disease state in an animal.
  • Optimal dosage levels for various animals can easily be determined by those skilled in the art, by evaluating, among other things, the composition's ability to (i) inhibit or reduce pathogenic bacteria in the gut at various doses, (ii) increase or maintain levels of beneficial bacteria and /or (iii) enhance animal health at various doses.
  • Example 1 Strain characteristics relevant to survival in the gastrointestinal tract.
  • Bacillus subtilis strains were screened from various environmental samples in order to obtain a superior strain as animal direct-fed microbial / probiotic. As the strain is intended to reach its full potential in the intestine of the target animal, the strain was pre-screened to withstand various environmental and gut related conditions. Strain spores were generated (Nicholson and Setlow 1990), washed and incubated at 80 °C for 20 minutes (pasteurization), then titrated in logarithmic / 1 in 10 dilutions using veal infusion broth agar (VI, DifcoTM, no. 234420, Becton Dickinson GmbH, Heidelberg, Germany).
  • the second highest dilution prior to no growth was stored at -80 °C and used as standardized starting point for all further assessments from spore state.
  • survival of acid exposure was assessed based on Larsen et al. (2014).
  • Growth of vegetative cells was furthermore assessed at low pH indicating growth under stomach/proventriculus and gizzard conditions, as well as in presence of up to 4 mM bile (B8631, CAS 8008-63-8, Sigma-Aldrich) at pH 7 in order to confirm strain growth at the proximal part of the small intestine right after clearance of the stomach or gizzard (Argenzio 2004b; Trampel and Duke 2004).
  • strain fitness in the anaerobe intestine was assessed by inoculating standardized spore solutions under anaerobic conditions (AnaeroPakTM, Thermo Fisher Scientific) in VI medium supplemented with 2.5 mM KNO3 (Glaser et al. 1995). Furthermore was the anaerobe proteolytic and cellulytic activity of strains assessed on VI agar plates supplemented with 1% skim milk powder (70166, Sigma-Aldrich) or 0.1% water insoluble AZCL-HE cellulose (I-AZCEL, Megazyme
  • Osmotic stress as also found in the gut (Argenzio 2004b; Trampel and Duke 2004), was assessed by determining growth on VI agar with addition of 5% NaCl (den Besten et al. 2009). Finally, spore heat stability was assessed to determine pelleting stability by exposing spores to 99 °C for 20 min (Palop et al. 1996) and subsequent inoculation on VI agar.
  • Bacillus subtilis strain DSM 32315 survived simulated gastric passage, growth of strain DSM 32315 was observed starting at pH 6. Strain DSM 32315 grew anaerobically and was able to degrade water- insoluble cellulose and protein under anaerobic conditions. Strain DSM 32315 was able to grow in presence of 2 and 4 mM bile, as well as in presence of 5% NaCl. Strain DSM 32315 reached an average spore count of 8.42 x 10 s CFU/mL, and spores of strain DSM 32315 were viable after exposure to 99°C for 20 min.
  • Reece, W. O. (ed.) Duke's Physiology of Domestic Animals; Twelfth Edition, Chapter 25; Georgia University Press, Ithaca, New York, USA.
  • Example 2 Comparative strain performance relative to state of the art direct-fed microbial (DFM) / probiotic for animal nutrition - quantitative assessment of bile tolerance.
  • DFM direct-fed microbial
  • strain DSM 32315 reached its maximum OD in presence of 2 mM bile 10 h faster than the benchmark Bacillus subtilis strain DSM 17299. In addition, strain DSM 32315 grew 2.4 fold faster during the first 5 hours, and 1.3 fold faster during the first 10 h of the test, compared to growth of benchmark strain DSM 17299, respectively.
  • Example 3 Comparative strain performance relative to state of the art direct-fed microbial (DFM) / probiotic for animal nutrition - growth in presence of short chain fatty acids (SCFA).
  • DFM direct-fed microbial
  • SCFA short chain fatty acids
  • Bacillus subtilis strain DSM 32142 was able to grow at pH 6 in the presence of acetic, propionic and lactic acid, whereas strain DSM 17299 was unable to grow from spore stage under these conditions.
  • Example 4 Comparative strain performance relative to state of the art direct-fed microbial (DFM) / probiotic for animal nutrition - quantitative assessment of enzymatic activity.
  • DFM direct-fed microbial
  • strains DSM 32315 and DSM 17299 were compared evaluating the respective carbohydrate degradation activity.
  • Cellulase and Xylanase activity were determined as described in Larsen et al. (2014). Analysis was performed in three independent runs, then averaged as milliunits per microliter solution, statistical analysis was performed using one-way ANOVA procedure of MiniTab ® 16 Statistical Software (Minitab Inc., State College, PA, USA). Results can be found in Table 4.1.
  • strain DSM 32315 demonstrated significant 7.5 fold increased cellulase and 2.1 fold increased xylanase activity comparing to benchmark strain DSM 17299.
  • Example 5 Comparative strain performance relative to state of the art direct-fed microbial (DFM) / probiotic for animal nutrition - expression of metabolites and pathogen inhibition.
  • DFM direct-fed microbial
  • strains DSM 32315 and benchmark strain DSM 17299 were compared evaluating the respective number of metabolites expressed and pathogens inhibited in the respective media.
  • starter cultures were grown and tests performed as described in Scholz et al. (2011). From 10 mL Luria Bertami broth (LB, Thermo Fisher Scientific) culture grown for 24 h at 37°C and 160 rpm in 100 mL flask, 100 uL were transferred to main culture. Main culture was grown either in 10 mL LB containing 0.2 mL / L KellyT trace metal solution (LBKelly, Scholz et al.
  • Clostridium perfringens inhibition via Bacillus subtilis bacteriocin production was assessed using well diffusion antagonismus test (Parente et al. 1995).
  • Four pathogenic C. perfringens candidates were tested being C. perfringens type strain ATCC 13124 from Teo and Tan (2005), as well as three pathogenic C. perfringens field isolates from poultry and swine, obtained from University of Leipzig, Faculty of Veterinary Medicine, Department of Bacteriology and Mycology, Prof. Dr. Christoph Baums, Potsdam, Germany. The C.
  • strains 2300-1-17 and 2300-1-18 were isolated from necrotic enteritis positive chicken digestive tract. Both strains produce a-toxin, strain 2300-1-17 also expressing NetB toxin (Sawa et al. 2013; Uzal et al. 2014,) whereas strain 2300-1-18 tested positive for ⁇ 2 -toxin (Allaart et al. 2012). Strain 2300-1-19 was isolated from digestive tract of a scouring piglet exhibiting symptoms of Clostridial type A enteritis (Songer and Uzal 2005). Growth conditions and media were described by Teo and Tan (2005).
  • Clostridium perfringens starter cultures were cultivated anaerobically (AnaeroPakTM, Thermo Fischer Scientific) in fluid thioglycolate broth (FTB, Becton Dickenson) for 24 h at 37°C and 160 rpm in 100 mL flask, then spread with sterile cotton swab agar plates (TSBYE with 1% agar, short TSAYE).
  • Inoculated TSAYE plates were then incubated anaerobically overnight at 37°C in order to obtain lawn of C. perfringens. After overnight growth, three 9 mm diameter wells were cut into the agar with lawn, 1 st well was used as non-inoculated control without culture, 2 nd well was inoculated with 100 uL not- C. perfringens-inhibiting Bacillus strain (B. cereus var. toyoi, NCIMB
  • Plantazolicin a novel microcin B17/streptolysin S-like natural product from Bacillus amyloliquefaciens FZB42. Journal of bacteriology, 193(1), 215-224.
  • a broiler growth performance study was conducted, using as-hatched Vencobb 400 (Venkateshwara Hatcheries Pvt. Ltd, India) day old chicks in a floor pens with used litter.
  • Four dietary treatments were randomly assigned, with twelve replicate pens per treatment containing 25 birds per pen. Birds were fed with one of the dietary treatments in three phases consisting of starter (1-14 days), grower (15-28 days) and finisher (29-42 days) phases.
  • the basal diet was mainly based on corn-soybean meal (Table 6.1) containing 500g/MT of dinotolmide to control coccidiosis.
  • the basal diet also included 4% meat and bone meal (MBM), as additional challenge as MBM is a predisposing factor for development of necrotic enteritis caused by Clostridium perfringens in broiler chickens (M'Sadeqa et al. 2015).
  • MBM meat and bone meal
  • Four treatments were mainly based on corn-soybean meal (Table 6.1) and included; 1. Basal control
  • Control Control + 50 g of Bacitracin Methylene Disalicyclate/MT of feed (BMD), 3. Control + a competitor product with Bacillus subtilis strain at 500 g/MT of feed with 1.6* 10 9 cfu/g (DSM 17299), 4. Control + a Bacillus subtilis strain DSM 32315 at 250 g/MT containing 2.0* 10 9 cfu/g (DSM 32315)
  • Experimental treatments were fed ad libitum in mash form from 1-42 days of age. Statistical analysis was performed using one-way ANOVA procedure and LSD post-test analysis with SAS vs9.4 (SAS Institute Inc., USA). The results of the treatments on body weight, feed conversion ratio and mortality are reported in Table 6.2. Table 6.1. Ingredient and nutrient composition of basal diet.
  • Soybean meal 48% CP 36.09 27.64 24.63
  • BW average bird body weight in specified time period
  • FCR feed conversion ratio calculated as feed to gain in specified time period
  • Control no additives in basal diet
  • BMD treatment with addition of bacitracin methylene disalicylate to basal diet
  • DSM 17299 treatment with addition of DSM 17299 to basal diet
  • DSM 32315 treatment with addition of strain DSM 32315 to basal diet
  • Difference the numeric difference observed when DSM 32315 was compared to control
  • Relative % the difference between DSM 32315 and control as a percent change from control.
  • DSM 32315 improved the FCR of broilers by 0.7% compared to the control. Body weight at 21 days was also improved by 2.1 % when DSM 32315 was fed to broilers compared to the control. While these improvements were not to the extent of that observed when the very potent antibiotic growth promoter BMD was utilized, DSM 32315 did improve broiler performance in this period to a greater extent than DSM 17299.
  • DSM 32315 was able to improve both body weight and feed conversion by 1.4% and -1.7% respectively. These improvements were again greater than those observed when the competitor product DSM 17299 was used. While day 42 body weight was still better in the antibiotic growth promoter group BMD, DSM 32315 treatment was able to reduce the FCR by an additional 0.01 (0.6%) compared to the BMD supplemented treatment group.
  • a broiler growth performance study was conducted with male, Ross 308 (Aviagen Asia, Thailand) day old chicks placed in floor pens with used litter. There were four dietary treatments, 16 replicate pens per treatment and 12 birds per pen. Birds were fed with one of the dietary treatments in three phases consisting of starter (1-14 days), grower (15-28 days) and finisher (29-42 days) phases.
  • the basal diet was mainly based on corn-soybean meal (Table 7.1) containing 60g salinomycin/MT of feed to control coccidiosis.
  • the basal diet also included 5% corn dried distiller's grains with solubles (DDGS), as the addition of DGGS, especially in starter diets, can reduce the rate of broiler growth (Lumpkins et al. 2004) and is a predisposing factor for development of necrotic enteritis caused by Clostridium perfringens in broiler chickens (Macklin et al. 2011).
  • the four dietary treatments included; 1. Basal control (Control), 2. Control + 20 g of Zinc Bacitracin /MT of feed (ZnB), 3. Control + a competitor product with Bacillus subtilis strain at 500 g/MT of feed with 1.6* 10 9 cfu/g (DSM 17299), 4.
  • Control + a Bacillus subtilis strain DSM 32315 at 250 g/MT containing 2.0* 10 9 cfu/g (DSM 32315).
  • the basal diet Statistical analysis was performed using one-way ANOVA procedure and LSD post-test analysis with SAS vs9.4 (SAS Institute Inc., USA). Animal growth performance 0-42 days can be found in Table 7.2.
  • Table 7.1 Ingredient and nutrient composition of basal diet.
  • BW average bird body weight in specified time period
  • FCR feed conversion ratio calculated as feed to gain in specified time period and adjusted for mortalities
  • Control no additives in basal diet
  • ZnB treatment with addition of zinc bacitracin
  • DSM 17299 treatment with addition of DSM 17299 to basal diet
  • DSM 32315 treatment with addition of strain DSM 32315 to basal diet
  • Difference the numeric difference observed when DSM 32315 was compared to control
  • Relative % the difference between DSM 32315 and control as a percent change from control.
  • DSM 32315 During the entire grow-out period between 1 and 42 days, treatment with DSM 32315 was able to reduce the FCR by 2.7%. While this effect was also observed with the other treatment groups, BMD and DSM 17299, DSM 32315 treatment also resulted in the heaviest final body weight with a 6.9% increase from the control. Additionally, DSM 17299 was able to reduce the mortality of birds by 2.25% compared to untreated controls and by 0.64% compared to DSM 17299.
  • a necrotic enteritis challenge study was conducted, using male Ross 308 (Aviagen) day old chicks in floor pens. Three dietary treatments were randomly assigned, with eleven replicate pens per treatment containing 14 birds per pen. Birds were fed with one of the dietary treatments in three phases consisting of starter (1-11 days), grower (12-25 days) and finisher (26-35 days) phases. The basal diet was mainly based on corn-soybean meal (Table 8.1). The starter diet was prepared as 2 mm crumbled pellets and the grower and finisher diets as 4 mm pellets. The three treatments included; 1. Basal control (Control), 2. Positive Control + Narasin Coccidiostat (Monteban® G100, Elanco USA) 650g/MT of feed
  • Necrotic enteritis is a disease of chickens caused by a predisposing Eimeria infection with a synergistic Clostridium perfringens infection that usually occurs in 3-4 week old broilers (Timbermont et al. 201 1).
  • the Necrotic Enteritis challenge was induced in two parts; at 12 days of age each bird received an oral inoculation of 5000 E. maxima oocytes and at 16 days of age each bird received 300 ⁇ 1 of an overnight culture of a field strain of Clostridium perfringens that was originally isolated from ileal contents of broiler chicks suffering from necrotic enteritis.
  • the results of the treatments on body weight, feed conversion ratio and mortality are reported in Table 8.2.
  • footpad lesion scores were also measured.
  • the footpads were scored from sampled birds for pododermatitis (i.e., foodpad disease) using scale from 0 (representing no evidence of pododermatitis) to 4 (severe pododermatitis) based on the Welfare Quality 2009 (Rushen et al. 201 1).
  • the results of the treatments on footpad lesion scores is reported in Table 8.3.
  • Clostridium perfringens at days 11, 18 and 35 is reported in Tables 8.4, 8.5 and 8.6 respectively.
  • Table 8.1 Ingredient and nutrient composition of basal diet.
  • Soybean meal 48% CP 40.06 35.45 30.33
  • BW average bird body weight
  • FCR feed conversion ratio calculated as feed to gain in specified time period
  • aFCR feed conversion ratio calculated as feed to gain and adjusted for mortalities in specified time period
  • Mortality the mortality from day 11-35 as a percentage of the pen population
  • Control no additives in basal diet
  • Narasin treatment with addition of narasin coccidiostat to basal diet
  • DSM 32315 treatment with addition of the novel Bacillus subtilis strain DSM 32315 to basal diet
  • Difference the numeric difference observed when DSM 32315 was compared to control
  • Relative % the difference between DSM 32315 and control as a percent change from control.
  • Control no additives in basal diet
  • Narasin treatment with addition of narasin coccidiostat to basal diet
  • DSM 32315 treatment with addition of the novel Bacillus subtilis strain DSM 32315 to basal diet
  • Difference the numeric difference observed when DSM 32315 was compared to control
  • Relative % the difference between DSM 32315 and control as a percent change from control.
  • Control no additives in basal diet
  • Narasin treatment with addition of narasin coccidiostat to basal diet
  • DSM 32315 treatment with addition of the novel Bacillus subtilis strain DSM 32315 to basal diet
  • Difference the numeric difference observed when DSM 32315 was compared to control.
  • Table 8.6 Molecular enumeration of Bacillus species and Clostridium perfringens in the ileum and cecum of broilers, with and without diet supplementation with B. subtilis based feed additive or Narasin at 35 days of age.
  • Control no additives in basal diet
  • Narasin treatment with addition of narasin coccidiostat to basal diet
  • DSM 32315 treatment with addition of the novel Bacillus subtilis strain DSM 32315 to basal diet
  • Difference the numeric difference observed when DSM 32315 was compared to control.
  • Example 9 Assessment of strain tolerance to feed pellet production and feed storage.
  • % Recovery of Spores calculated as the percentage of spores counted in relation to the spores counted at 0 weeks of storage directly after pelleting.
  • E. cecorum is known to cause lameness, arthritis and osteomyelitis in broilers usually caused by an inflammation of a joint and/or bone tissue. Additional E. cecorum can cause an inflammation of the pericardium [Kense et al. 2011]. DSM 20683 was isolated from caecum of a chicken.
  • S. gallinaceus can cause septicaemia in poultry.
  • the gross lesions included splenomegaly, hepatomegaly, renomegaly and congestion. Multiple areas of necrosis and/ or infarction in the liver and spleen associated with valvular endocarditis were also observed [Collins et al. 2002].
  • ATCC 43765 belongs to Serological group: R; serovar 2 and was isolated from pigs.
  • Bacillus strains were grown in 10 mL TSBYE (30 g/1 TSB + 6 g/1 Yeast extract) or LB-Kelly (LB- Media supplemented with trace elements solution of DSMZ media 1032) for 16 h at 37°C and 200 rpm in 100 mL shaking flask.
  • the pathogenic strains were grown under suitable conditions as liquid culture to an optical density of 595 nm of at least 1, then 100 ⁇ were spread with sterile spatula on the surface of agar plates.
  • S. gallinaceus BHI agar plates for E. cecorum and S. suis TSBYE agar plates are used. Three 9 mm diameter wells were cut into the dried plates.
  • DSM 32315 is able to inhibit the growth of is. cecorum, S. gallinaceus and S. suis very effectively, in particular in comparison to DSM 17299.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Pest Control & Pesticides (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)

Abstract

The current invention concerns a new B. subtilis strain with strong inhibition of C. perfringens and its use as probiotic.

Description

Bacillus subtilis strain with probiotic activity The current invention concerns a new B. subtilis strain with strong inhibition of C. perfringens and its use as probiotic.
The use of B. subtilis strains as probiotic ingredient in the feed industry is well known in the state of the art. The function of probiotics (also called "direct- fed microbials" or "DFM") is to influence the gut microflora in a positive way by supporting the growth of beneficial bacteria and/or the suppression of the growth of pathogenic bacteria. Ideally, by using probiotics the use of antibiotic growth promotors (AGPs) becomes redundant. But besides that, it is desirable that the probiotic fulfills further functions like helping in the digestion of specific feed ingredients. Thus in view of the state of the art, there is a need for probiotics which influence the gut microflora in a positive way and beyond that desirably fulfill at least one further function.
Surprisingly it was found that the bacteria according to the current invention exhibit many advantageous features. Besides their ability to inhibit growth of C. perfringens, the main commercially relevant pathogen of poultry, they in particular show a very high proliferation rate in presence of bile and help to digest cellulose in a very effective way.
Bacillus subtilis DSM 32315 has been identified by screening of naturally occurring isolates. It has been deposited with the DSMZ on May 12, 2016 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure under the Accession Number as mentioned before in the name of Evonik Degussa GmbH.
Thus a first subject of the current invention is a Bacillus subtilis strain and/or a preparation of said Bacillus subtilis strain selected from the following group:
a) The Bacillus subtilis strain as deposited under DSM 32315 at the DSMZ;
b) a mutant of the Bacillus subtilis strain as deposited under DSM 32315 having all identifying characteristics of the strain DSM 32315, wherein said mutant preferably has a DNA sequence identity to the strain DSM 32315 of at least 95%, preferably at least 96, 97 or 98 %, more preferably at least 99 or 99.5 %;
c) a preparation of (a) or (b);
d) a preparation containing an effective mixture of metabolites as contained in (a), (b) or (c). The Bacillus subtilis strain as deposited under DSM 32315 at the DSMZ exhibits the following characterizing sequences:
a) a 16S rDNA sequence with a sequence identity of at least 99.5 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 1;
b) a yqfD sequence with a sequence identity of at least 99.5 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 2;
c) a gyrB sequence with a sequence identity of at least 99.5 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 3;
d) an rpoB sequence with a sequence identity of at least 99.5 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 4;
e) a groEL sequence with a sequence identity of at least 99.5 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 5.
Thus, a further subject of the current invention is a Bacillus subtilis strain or a preparation thereof, in particular a B. subtilis strain with the characteristics as mentioned before, exhibiting at least one, preferably all, of the following characteristics:
a) a 16S rDNA sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 1;
b) a yqfD sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 2; c) a gyrB sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 3. Preferably, this B. subtilis strain exhibits at least one, more preferably all, of the following further characteristics:
d) an rpoB sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 4;
e) a groEL sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.8 or 99.9 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 5.
Thus, a particular subject of the current invention is also a Bacillus subtilis strain, exhibiting the following characteristics:
a) a 16S rDNA sequence according to SEQ ID NO: 1;
b) a yqfD sequence according to SEQ ID NO: 2;
c) a gyrB sequence according to SEQ ID NO: 3. Preferably, this B. subtilis strain exhibits the following further characteristics:
d) an rpoB sequence according to SEQ ID NO: 4;
e) a groEL sequence according to SEQ ID NO: 5. The strains of the current invention are preferably characterized by at least one, more preferably by all, of the following further features:
They are preferably able to grow under anaerobic conditions. Further, they are preferably able to degrade water-insoluble cellulose as well as protein under such anaerobic conditions.
They preferably inhibit infectious bacteria, in particular C. perfringens, very effectively. In particular they are preferably characterized by a pathogen clearance of at least 10 mm, more preferably at least 13 mm, in a well diffusion antagonism assay on LBKelly agar plates with respect to C. perfringens type strain ATCC 13124.
The spores are preferably viable at low pHs and preferably survive exposure to pHs as low as 4.0, in particular as low as 3.0, preferably as low as 2.0, for at least one hour.
The strains according to the invention are preferably further characterized by being able to grow in the presence of 0.05 wt.-% acetic acid, 0.05 wt.-% propionic acid and/or 0.2 wt.-% lactic acid.
They are preferably further characterized by a cellulase activity of at least 200 mU/mL, more preferably at least 300 mU/mL, in particular at least 350 mU/mL, above all about 369 mU/mL, and by a xylanase activity of at least 15 mU/mL, more preferably at least 20 mU/mL, in particular at least 25 mU/mL, above all about 33 mU/mL.
The B. subtilis strains according to the invention are preferably further characterized by being able to grow in presence of 2 mM bile, more preferably in presence of 4 mM bile. In particular they are preferably characterized by an AUC5 performance value of at least 0.5, preferably at least 0.65, above all at least 0.8, in particular about 0.88, and an AUC10 performance value of at least 1.2, preferably at least 1.4, above all at least 1.6, in particular about 1.7, in presence of 2 mM bile, respectively.
In addition, the strains are preferably able to grow under high salt conditions, in particular in presence of 5 wt.-% of NaCl, for at least one day.
Further the strains of the current invention preferably survive the high temperatures necessary for pelleting animal feed, in particular they preferably survive a temperature of 80°C for at least 20 minutes. Without wishing to be bound by any theory, it is thought that the Bacillus subtilis strains according to the current invention enhance animal health by a multifaceted mode of action, including the production of antibacterial metabolites with selective efficacy and the competition with pathogenic bacteria by better consuming the available nutrients, thereby suppressing effective establishment of pathogenic bacteria in the gut.
It is a big advantage of probiotics in comparison to antibiotics, that they do not destroy bacteria indiscriminately nor do they lead to antibiotic resistant strains of pathogenic bacteria. Normally they are able to selectively compete with pathogenic bacteria by production of antimicrobial substances with specific efficacy, and are ideally able to simultaneously enhance the growth and viability of beneficial gut microflora. Further, they are preferably able to stimulate a systemic immune response in the treated animals.
The mutant strains of DSM 32315 of the current invention are preferably spontaneous mutants. The term "spontaneous mutant" refers to mutants that arise from DSM 32315 without the intentional use of mutagens. Such spontaneous mutants may be obtained by classical methods, such as growing the Bacillus subtilis strain in the presence of UV light or in the presence of a certain antibiotic to which the parent is susceptible and testing any resistant mutants for improved biological activity or improved ability to enhance one or more of the indicia of animal health. Other methods for identifying spontaneous mutants are known to those of ordinary skill in the art. But besides these preferred spontaneous mutants all other kinds of mutants of DSM 32315, like mutants obtained by genetic engineering, are also comprised by the current invention.
One particular embodiment of the current invention are naturally non-occurring mutants of the strain DSM 32315 characterized by the features as mentioned before.
In a preferred embodiment of the current invention, the strains and preparations of the present invention are preferably administered orally to animals or human beings. Thus, a further subject of the current invention are compositions, such as feedstuffs, foodstuffs, drinking and rearing water as well as therapeutic compositions, containing a B. subtilis strain and/or a preparation of the current invention.
A further subject of the current invention is also the use of a B. subtilis strain and/or a preparation of the current invention as a probiotic ingredient (DFM) in feed or food products.
Preferred foodstuffs according to the invention are dairy products, in particular yoghurt, cheese, milk, butter and quark. The cells of the strains of the current invention may be present, in particular in the compositions of the current invention, as spores (which are dormant), as vegetative cells (which are growing), as transition state cells (which are transitioning from growth phase to sporulation phase) or as a combination of at least two, in particular all of these types of cells. In a preferred embodiment, the composition of the current invention comprises mainly or only spores.
The Bacillus subtilis strains of the current invention and compositions containing them, when administered to animals, preferably enhance the health of such animals and/or improve the general physical condition of such animals and/or improve the feed conversion rate of such animals and/or decrease the mortality rate of such animals and/or increase the survival rates of such animals and/or improve the weight gain of such animals and/or increase the productivity of such animals and/or increase the disease resistance of such animals and/or increase the immune response of such animals and/or establish or maintain a healthy gut microflora in such animals and/or reduce the pathogen shedding through the feces of such animals. In particular the strains and compositions of the current invention might be used to assist in re-establishing a healthy balance of the gut microflora after administration of antibiotics for therapeutic purposes.
A further subject of the current invention is therefore a method of enhancing the health of animals and/or of improving the general physical condition of animals and/or of improving the feed conversion rate of animals and/or of decreasing the mortality rate of animals and/or of increasing the survival rates of animals and/or of improving the weight gain of animals and/or of increasing the productivity of animals and/or of increasing the disease resistance of animals and/or of increasing the immune response of animals and/or of establishing or maintaining a healthy gut microflora in animals and/or of reducing the pathogen shedding through the feces of animals, wherein the strains and/or preparations of the current invention or the compositions of the current invention, which comprise such strain(s), are administered to animals.
A further subject of the current invention is therefore also the use of strains and/or preparations and/or compositions of the current invention for enhancing the health of animals and/or for improving the general physical condition of animals and/or for improving the feed conversion rate of animals and/or for decreasing the mortality rate of animals and/or for increasing the survival rates of animals and/or for improving the weight gain of animals and/or for increasing the productivity of animals and/or for increasing the disease resistance of animals and/or for increasing the immune response of animals and/or for establishing or maintaining a healthy gut microflora in animals and/or for reducing the pathogen shedding through the feces of animals, wherein the strains and/or preparations of the current invention or the compositions of the current invention, which comprise such strain(s), are administered to animals. A further subject of the current invention are therefore also the strains and preparations of the current invention as mentioned before and the compositions of the current invention, containing those strains, for enhancing the health of animals and/or for improving the general physical condition of animals and/or for improving the feed conversion rate of animals and/or for decreasing the mortality rate of animals and/or for increasing the survival rate of animals and/or for improving the weight gain of animals and/or for increasing the productivity of animals and/or for increasing the disease resistance of animals and/or for increasing the immune response of animals and/or for establishing or maintaining a healthy gut microflora in animals and/or for reducing the pathogen shedding through the feces of animals.
"Increasing the productivity of animals" refers in particular to any of the following: production of more or higher quality eggs, milk or meat or increased production of weaned offspring.
The methods and uses of the strains, preparations and compositions of the current invention can be therapeutic or non-therapeutic. In a particularly preferred embodiment of the current invention, the methods and uses are non-pharmaceutic, in particular feeding applications.
As the untreated manure of animals due to pathogenic bacteria and other ingredients may have a detrimental environmental effect, in particular with respect to the animals themselves and/or with respect to human beings getting in contact with the manure, which can be avoided by either feeding the animals or directly treating the manure or the bedding of the animals with the strains, compositions or preparations of the current invention, therefore a further subject of the current invention is a method of controlling and/or avoiding detrimental environmental effects of manure or contaminated liquids, the method comprising the step of applying to manure, contaminated liquids, litter, a pit, or a manure pond at least one strain, one preparation and/or one composition according to the current invention.
Preferably the composition is applied in liquid form, for example by spraying, or as a powder, for example by strewing.
As detrimental bacteria may have a negative influence on the consistency of litter and in particular may effect a rather fluid or highly fluid litter, which might lead to foot pad lesions of poultry and which can be avoided by feeding the animals with the strains, compositions or preparations of the current invention, therefore a further subject of the current invention is a method of controlling and/or improving the consistency of litter, in particular a method of ensuring a solid consistency of litter and/or a method of avoiding foot pad lesions, the method comprising the step of feeding animals, in particular poultry, with at least one strain, one preparation and/or one composition according to the current invention. The strains and preparations according to the invention can also be used for improving the quality of water. A further subject of the current invention is therefore also a method of controlling and/or improving the quality of water or aqueous solutions, in particular of drinking water and/or rearing water, comprising the step of applying to water or an aqueous solution at least one strain and/or at least one preparation and/or at least one composition of the current invention.
Further, the strains and preparations according to the invention can also be used for treating microbial diseases of plants. A further subject of the current invention is therefore also a method of treating and/or preventing microbial diseases of plants, in particular of cultivated plants, comprising the step of applying to the plants at least one strain and/or at least one preparation and/or at least one composition of the current invention. The application may be carried out in liquid form, such as by spraying, or in solid form, in particular as a powder.
By using the strains, preparations and compositions of the current invention preferably an improvement of at least one of the features as mentioned before is realized, wherein realization of the feature preferably means an improvement of at least 1 %, more preferably of at least 3 or at least 5 %, in comparison to an adequate negative control. As negative control averages known in the animal husbandry field may be used, but preferably as negative control animals which are subjected to the same treatment like the animals tested are used, but without administration of the strains and/or preparations of the current invention.
In particular, the strains, preparations and compositions of the current invention may be administered or fed to an animal in an amount effective to inhibit and/or decrease the growth of pathogenic bacteria in the animal gut. Such pathogenic bacteria include Clostridia, Listeria, Salmonella, Enterococci, Staphylococci, Aeromonas, Streptococci, Campylobacter, Escherichia coli, and Vibrio. Relatedly, the methods of the present invention may be used to decrease the amount of pathogenic bacteria shed in animal feces. The methods of the present invention may also be used to maintain or increase the growth of beneficial bacteria, such as lactic acid bacteria, in the animal gut. By decreasing pathogenic bacteria and/or increasing or maintaining beneficial bacteria, the compositions of the present invention are able to maintain an overall healthy gut microflora.
Thus, a further subject of the current invention is a method of inhibiting and/or decreasing the growth of harmful or pathogenic bacteria and/or maintaining and/or increasing the growth of beneficial bacteria in an animal gut, wherein strains and/or preparations and/or compositions of the current invention are administered to animals and wherein the pathogenic bacteria are preferably selected from Clostridia, in particular C. perfringens and C. difficile, Listeria, in particular L. monocytogenes, L. seeligeri and L. welshimeri, Salmonella, in particular S. enterica, S. gallinarum, S. pullorum, S. arizonae, S.
typhimurium, S. enteritidis, and S. bongori, Enterococci, in particular E. faecalis, E. faecium and E. cecorum, Staphylococcus, in particular S. aureus, Aeromonas, Streptococci, in particular S. suis and S. gallinaceus, Campylobacter, in particular C. jejuni and C. coli, Escherichia coli, and Vibrio, in particular V. parahemolyticus and V. harveyi, and the beneficial bacteria are preferably selected from lactic acid bacteria, in particular from Lactobacilli, and Bifidobacteria.
In a preferred embodiment of the invention the amount of at least one pathogenic bacterium, in particular the amount of C. perfringens, is reduced by at least 0.5 log, more preferably by at least 1 log, 2 log, or 3 log. Thus, a further subject of the current invention are also the strains, preparations and compositions of the current invention for inhibiting and/or decreasing the growth of pathogenic bacteria and/or for maintaining and/or increasing the growth of beneficial bacteria in an animal gut, wherein the pathogenic bacteria are preferably selected from Clostridia, in particular C. perfringens and C. difficile, Listeria, in particular L. monocytogenes, L. seeligeri and L. welshimeri, Salmonella, in particular S. enterica, S. gallinarum, S. pullorum, S. arizonae, S. typhimurium, S. enteritidis, and S. bongori, Enterococci, in particular E. faecalis, E. faecium and E. cecorum, Staphylococcus, in particular S. aureus, Aeromonas, Streptococci, in particular S. suis and S. gallinaceus, Campylobacter, in particular C. jejuni and C. coli, Escherichia coli, and Vibrio, in particular V. parahemolyticus and V. harveyi, and the beneficial bacteria are preferably selected from lactic acid bacteria, in particular from Lactobacilli, and Bifidobacteria.
The occurrence and/or increased growth of the pathogenic bacteria does or can lead to the outbreak of certain diseases. For example the occurrence and/or increased growth of Clostridium perfringens can lead to the outbreak of gut diseases, in particular to the outbreak of necrotic enteritis in poultry. The occurrence and/or increased growth of Clostridium perfringens can also lead to the outbreak of further diseases like bacterial enteritis, gangrenous dermatitis and colangiohepatitis. Even the mildest form of infection by C. perfringens can already be accompanied by diarrhea, which results in wet litter and by that may lead to secondary diseases like foot pad dermatitis.
A further subject of the current invention is therefore also a therapeutic composition comprising the strains and/or compositions of the current invention as mentioned before.
A preferred subject in this context is therefore a therapeutic composition for treatment and/or prevention of necrotic enteritis, in particular sub-clinical necrotic enteritis, in animals, preferably poultry, comprising the strains and/or compositions of the current invention as mentioned before.
Another preferred subject in this context is therefore a therapeutic composition for treatment and/or prevention of bacterial enteritis, gangrenous dermatitis, colangiohepatitis, clostridiosis, diarrhea and/or foot pad dermatitis, in animals, preferably poultry, comprising the strains and/or compositions of the current invention as mentioned before. A further subject of the current invention is therefore also the treatment and/or prevention of a disease, in particular of a gut disease, preferably of necrotic enteritis, in particular of sub-clinical necrotic enteritis, in poultry, wherein a strain and/or composition and/or preparation of the current invention is administered to an animal in need thereof.
A further subject of the current invention is therefore also the treatment and/or prevention of a disease, preferably a disease of poultry, selected from bacterial enteritis, gangrenous dermatitis,
colangiohepatitis, clostridiosis, diarrhea and/or foot pad dermatitis, wherein a strain and/or composition and/or preparation of the current invention is administered to an animal in need thereof.
The strains and/or preparations and/or compositions of the current invention can be administered to animals in feed and/or drinking water over multiple days throughout the animal's life or during particular stages or portions of the animal's life. For example, the strains and/or compositions can be administered only in a starter diet or only in a finisher diet of farm animals.
A particular subject of the current invention is also a method of enhancing the health of human beings and/or of improving the general physical condition of human beings and/or of increasing the disease resistance of human beings and/or of increasing the immune response of human beings and/or of establishing or maintaining a healthy gut microflora in human beings, wherein the strains and/or preparations of the current invention or the compositions of the current invention, which comprise such strain(s), are administered to human beings.
A further subject of the current invention is therefore also the use of strains and/or preparations and/or compositions of the current invention for enhancing the health of human beings and/or for improving the general physical condition of human beings and/or for increasing the disease resistance of human beings and/or for increasing the immune response of human beings and/or for establishing or maintaining a healthy gut microflora in human beings, wherein the strains and/or preparations of the current invention or the compositions of the current invention, which comprise such strain(s), are administered to human beings. The compositions of the present invention, in particular the feed, food and pharmaceutical compositions as well as the drinking or rearing water, preferably comprise the strains of the current invention and are administered to animals at a rate of about lxlO3 to about 2x1012 CFU/g feed or ml water, in particular in a rate of about lxlO3 or about lxlO4 or about lxlO5 or about lxlO6 or about lxlO7 or about lxlO8 or about lxlO9 or about lxlO10 or about lxlO11 or about lxlO12 CFU/g feed or ml water, preferably in an amount of about lxlO4 to about lxlO10 CFU/g feed or ml water, more preferably in an amount of lxl 04 to lxlO7 CFU/g feed or ml water. Correspondingly, preferred amounts of the strains and/or preparations of the current invention in the feed, food and water compositions of the current invention range preferably from 0.1 wt.-% to 10 w - %, more preferably from 0.2 wt.-% to 5 wt.-%, in particular from 0.3 wt.-% to 3 wt.-%. The methods of the present invention may be used for all kind of animals, in particular all kind of non- human and non-insect animals, more preferably all kind of vertebrates such as mammals, aquatic animals and birds.
Animals that may benefit from the current invention include but are not limited to farm animals, pets, exotic animals, zoo animals, aquatic animals, animals used for sports, recreation or work.
Pets are preferably selected from dogs, cats, domestic birds and domestic exotic animals.
Aquatic animals are preferably selected from finfish and crustaceans which are preferably intended for human nutrition. These include, in particular, carp, tilapia, catfish, tuna, salmon, trout, barramundi, bream, perch, cod, shrimps, lobster, crabs, prawns and crayfish. Preferred types of salmon in this context are the Atlantic salmon, red salmon, masu salmon, king salmon, keta salmon, coho salmon, Danube salmon, Pacific salmon and pink salmon. Further preferred aquatic animals are fanning fish which are subsequently processed to give fish meal or fish oil. In this connection, the fish are preferably herring, pollack, menhaden, anchovies, capelin or cod.
In a further preferred embodiment, the animals are farm animals, which are raised for consumption or as food-producers, such as poultry, swine and ruminants.
The poultry may be selected from productive or domestic poultry, but also from fancy poultry or wild fowl.
Preferred productive poultry in this context are chickens, turkeys, ducks and geese. The productive livestock in this context is preferably poultry optimized for producing young stock or poultry optimized for bearing meat.
Preferred fancy poultry or wild fowl are peacocks, pheasants, partridges, chukkars, guinea fowl, quails, capercaillies, grouse, pigeons and swans, with quails being especially preferred.
Further preferred poultry are ratites, in particular ostriches and emus, as well as parrots. Ruminants according to the current invention are preferably selected from cattle, goat and sheep. In one embodiment, the compositions of this invention may be fed to preruminants to enhance their health and, in particular, to decrease the incidence of diarrhea in these animals. Preruminants are ruminants, including calves, ranging in age from birth to about twelve weeks.
The compositions of the current invention may comprise at least one carrier or typical feed ingredients or combinations thereof.
Suitable carriers are inert formulation ingredients added to improve recovery, efficacy, or physical properties and/or to aid in packaging and administration. Such carriers may be added individually or in combination. These carriers may be selected from anti-caking agents, anti-oxidation agents, bulking agents, and/or protectants. Examples of useful carriers include polysaccharides (in particular starches, maltodextrins, methylcelluloses, gums, chitosan and/or inulins), protein sources (in particular skim-milk powder and/or sweet- whey powder), peptides, sugars (in particular lactose, trehalose, sucrose and/or dextrose), lipids (in particular lecithin, vegetable oils and/or mineral oils), salts (in particular sodium chloride, sodium carbonate, calcium carbonate, chalk, limestone, magnesium carbonate, sodium phosphate, calcium phosphate, magnesium phosphate and/or sodium citrate), and silicates (in particular clays, in particular beolite clay, amorphous silica, fumed/precipitated silicas, zeolites, Fuller's earth, baylith, clintpolite, montmorillonite, diatomaceous earth, talc, bentonites, and/or silicate salts like aluminium, magnesium and/or calcium silicate). Suitable carriers for animal feed additives are set forth in the American Feed Control Officials, Inc.' s Official Publication, which publishes annually. See, for example Official Publication of American Feed Control Officials, Sharon Krebs, editor, 2006 edition, ISBN 1-878341-18-9. The carriers can be added after concentrating the fermentation broth and/or during and/or after drying. Preferred carriers according to the invention are selected from calcium carbonate, diatomaceous earth and vegetable oil.
A preferred embodiment of the current invention are concentrate compositions, in particular feed additive compositions, i.e. compositions suitable for preparing a feed composition, which comprise at least one strain of the current invention and at least one carrier as mentioned before, wherein the at least one strain is preferably comprised in an amount of 0.1 to 10 wt.-%, more preferably in an amount of 0.2 to 5 wt.-%, in particular in an amount of 0.3 to 3 wt.-%, above all in an amount of 0.4 to 2.2 wt.-%, and the at least one carrier is preferably comprised in an amount of at least 90 wt.-%, preferably in an amount of 90 to 99.9 wt.-%, more preferably in an amount of 95 to 99.8 wt.-%, in particular in an amount of 97 to 99.7 wt.-%, above all in an amount of 97.8 to 99.6 wt.-%, and wherein the carrier consists preferably substantially of limestone, in particular of limestone with smaller parts of diatomaceous earth and/or vegetable oil. These preferred compositions of the current invention, which contain stabilized strains, can be used for the preparation of feed and pharmaceutical compositions as well as drinking and rearing water which preferably comprise the strains according to the invention in an amount as mentioned in the specification above. In a preferred embodiment 200 to 1000 grams of such a concentrate composition, in particular 250, 500 or 1000 grams of such a concentrate composition, are used per ton of feed, drinking or rearing water to provide compositions which can be used for feeding animals. These concentrate compositions preferably comprise at least one strain of the current invention in an amount of lxlO9 to 2xlOu CFU, in particular 2xl09 to lxlO11 CFU, per g of the concentrate composition. Starting from these concentrate compositions, feed and food compositions can be prepared by mixing the concentrate compositions with typical feed or food ingredients, respectively.
Suitable typical animal feed ingredients which may be contained in the compositions according to the invention and/or used in the preparation of feed compositions starting from concentrate compositions according to the invention include one or more of the following: proteins, carbohydrates, fats, further probiotics, prebiotics, enzymes, vitamins, immune modulators, milk replacers, minerals, amino acids, coccidiostats, acid-based products and/or medicines, such as antibiotics.
Carbohydrates containing components which may be used according to the invention are for example forage, roughage, wheat meal, sunflower meal or soya meal, and mixtures thereof.
Proteins containing components which may be used according to the invention are for example soya protein, pea protein, wheat gluten or corn gluten, and mixtures thereof.
Fats containing components which may be used according to the invention are in particular oils, of both animal and plant origin, like vegetable oils, for example soya bean oil, rapeseed oil, sunflower seed oil, flaxseed oil or palm oil, fish oil, and mixtures thereof.
Proteins containing components which additionally contain fats which may be used according to the invention are for example fish meal, krill meal, bivalve meal, squid meal or shrimp shells, as well as combinations thereof.
Further probiotics (DFM) which may be used according to the invention in combination with the strains and preparations of the invention are preferably bacteria selected from the species Bacillus subtilis, Bacillus licheniformis, Bacillus lentus, Bacillus pumilus, Bacillus laterosporus, Bacillus coagulans, Bacillus alevi, Bacillus cereus, Bacillus badius, Bacillus thurigiensis, Enterococcus faecium, and
Pediococcus acidilactici. Preferred examples are Bacillus licheniformis DSM 32314 (as deposited with the DSMZ on May 12, 2016 under the provisions of the Budapest Treaty on the International
Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure) and derivatives thereof, Bacillus subtilis PB6 (as described in US Patent No. 7,247,299 and deposited as ATCC Accession No. PTA-6737), which is sold by Kemin under the trademark CLOSTAT®, Bacillus subtilis C-3102 (as described in US Patent No. 4,919,936 and deposited as FERM BP- 1096 with the
Fermentation Research Institute, Agency of Industrial Science and Technology, in Japan), sold by Calpis as CALSPORTN®, Bacillus subtilis DSM 17299, as sold by Chr. Hansen under the trademark GalliPro®, a mixture of Bacillus subtilis DSM 17299 and Bacillus licheniformis DSM 17236, as sold by Chr. Hansen under the trademark GalliProTect®, a mixture of Bacillus licheniformis and Bacillus subtilis spores sold by Chr. Hansen under the trademark BIOPLUS2B®, or Bacillus coagulans strains as described in US Patent No. 6,849,256. Other non-Bacillus probiotics, such as Saccharomyces cerevisiae, Pichia pastoris, Aspergillus niger, Aspergillus oryzae, or Hansenula, may also be used in compositions of the present invention. In particular in food compositions further probiotics which are known to be useful to the human health may be used such as lactic acid producing bacteria, in particular lactobacilli, or Bifidobacteria. If said further probiotics are not formulated as part of the compositions of the present invention, they may be administered together (either at the same time or at different times) with the compositions of the present invention.
Prebiotics which may be used according to the invention are preferably oligosaccharides, in particular selected from galactooligosaccharides, silayloligosaccharides, lactulose, lactosucrose,
fructooligosaccharides, palatinose or isomaltose oligosaccharides, glycosyl sucrose,
maltooligosaccharides, isomaltooligosaccharides, cyclodextrins, gentiooligosaccharides, soybean oligosaccharides, xylooligosaccharides, dextrans, pectins, polygalacturonan, rhamnogalacturonan, mannan, hemicellulose, arabinogalactan, arabinan, arabinoxylan, resistant starch, mehbiose, chitosan, agarose, inulin, tagatose, polydextrose, and alginate.
Enzymes which may be used in feed compositions according to the invention and which may aid in the digestion of feed, are preferably selected from phytases (EC 3.1 .3.8 or 3.1.3.26), xylanases (EC
3.2.1.8), galactanases (EC 3.2.1 .89), galactosidases, in particular alpha-galactosidases (EC 3.2.1.22), proteases (EC 3.4), phospholipases, in particular phospholipases Al (EC 3.1 .1.32), A2 (EC 3.1.1.4), C (EC 3.1.4.3), and D (EC 3.1.4.4), lysophospholipases (EC 3.1 .1.5), amylases, in particular alpha- amylases (EC 3.2.1.1 ); lysozymes (EC 3.2.1 .17), glucanases, in particular beta-glucanases (EC 3.2.1.4 or EC 3.2.1.6), glucoamylases, cellulases, pectinases, or any mixture thereof.
Examples of commercially available phytases include Bio-Feed™ Phytase (Novozymes), Ronozyme® P and HiPhos™ (DSM Nutritional Products), Natuphos™ (BASF), Finase® and Quantum® Blue (AB Enzymes), the Phyzyme® XP (Verenium/DuPont) and Axtra® PHY (DuPont). Other preferred phytases include those described in e.g. WO 98/28408, WO 00/43503, and WO 03/066847.
Examples of commercially available xylanases include Ronozyme® WX and G2 (DSM Nutritional Products), Econase® XT and Barley (AB Vista), Xylathin® (Verenium) and Axtra® XB (Xylanase/beta-glucanase, DuPont). Examples of commercially available proteases include Ronozyme® Pro Act (DSM Nutritional Products).
Vitamins which may be used according to the invention are for example vitamin A, vitamin D3, vitamin E, vitamin K, e.g., vitamin K3, vitamin B 12, biotin, choline, vitamin B 1 , vitamin B2, vitamin B6, niacin, folic acid and panthothenate, e.g. , Ca-D-panthothenate, or combinations thereof.
Immmune modulators which may be used are for example antibodies, cytokines, spray-dried plasma, interleukins, or interferons, or combinations thereof.
Minerals which may be used according to the invention are for example boron, cobalt, chloride, chromium, copper, fluoride, iodine, iron, manganese, molybdenum, selenium, zinc, calcium, magnesium, potassium, or sodium, or combinations thereof. Amino acids which may be used according to the invention are for example lysine, alanine, threonine, methionine or tryptophan, or combinations thereof.
Thus, a further embodiment of the current invention is a method of preparing an animal feed composition comprising mixing at least one strain and/or at least one preparation and/or at least one concentrate composition of the current invention, in particular in an amount effective to enhance animal health, with feed ingredients, such as proteins, lipids and/or carbohydrates, and optionally further beneficial substances, preferably as mentioned before, to provide a feeding product. This method may comprise for example also a pelleting step.
Standard pelleting processes known to those of skill in the art may be used, including extrusion processing of dry or semi-moist feeds. Preferred pelleting temperatures are between about 65° C and about 120° C.
The strains and compositions of the present invention can be obtained by culturing the strains of the current invention according to methods well known in the art, including by using the media and other methods as described for example in US 6,060,051, EP0287699 or US2014/0010792. Conventional large-scale microbial culture processes include submerged fermentation, solid state fermentation, or liquid surface culture. Towards the end of fermentation, as nutrients are depleted, the cells of the strains begin the transition from growth phase to sporulation phase, such that the final product of fermentation is largely spores, metabolites and residual fermentation medium. Sporulation is part of the natural life cycle of these strains and is generally initiated by the cell in response to nutrient limitation.
Fermentation is configured to obtain high levels of colony forming units of the Bacillus subtilis cells and to promote sporulation. The bacterial cells, spores and metabolites in culture media resulting from fermentation may be used directly or concentrated by conventional industrial methods, such as centrifugation, tangential-flow filtration, depth filtration, and evaporation. The concentrated fermentation broth may be washed, for example via a diafiltration process, to remove residual fermentation broth and metabolites. The fermentation broth or broth concentrate can be dried with or without the addition of carriers using conventional drying processes or methods such as spray drying, freeze drying, tray drying, fluidized-bed drying, drum drying, or evaporation. The resulting dry products may be further processed, such as by milling or granulation, to achieve a specific particle size or physical format. Carriers, as described above, may also be added post-drying.
Preparations of the strains of the current invention may be cell-free preparations or preparations containing cell debris or preparations containing a mixture of intact cells and cell debris.
Cell-free preparations of the strains of the current invention can be obtained for example by centrifugation and/or filtration of fermentation broth. Depending on the technique used, these cell- free preparations may not be completely devoid of cells, but may still comprise a smaller amount of cells. As the cells secret compounds like metabolites, enzymes and/or peptides into the surrounding medium, the supernatant of the cells comprises a mixture of such compounds, in particular metabolites, enyzmes and/or peptides, as secreted by the cells. Thus, in a preferred embodiment of the invention, the preparation of the strains is a supernatant of the fermentation broth.
Compositions comprising cell debris of the strains may be obtained by rupturing the cells applying techniques as known to those of skill in the art, for example by mechanical means or by applying high pressure. Depending on the degree of force applied, a composition comprising only ruptured cells or a composition comprising a mixture of cell debris and intact cells is obtained. Homogenization of the cells may be realized for example by utilizing a French cell press, sonicator, homogenizer,
microfluidizer, ball mill, rod mill, pebble mill, bead mill, high pressure grinding roll, vertical shaft impactor, industrial blender, high shear mixer, paddle mixer, and/or polytron homogenizer. Suitable alternatives are enzymatic and/or chemical treatment of the cells. Cell-free preparations of the current invention comprise also preparations which are obtained by first rupturing the cells by applying techniques as mentioned before and subsequently removing the cell debris and the remaining intact cells. Removing of the cell debris and remaining intact cells can be carried out in particular by centrifugation and/or filtration. The preparations of the strains of the current invention may comprise as active compounds at least one metabolite, preferably a mixture of metabolites, as further described below, and/or at least one enzyme selected from proteases, in particular subtilisin, xylanases and/or cellulases, and/or at least one peptide, and/or combinations thereof. A preparation containing an effective mixture of metabolites as contained in the strains of the current invention and/or as contained in the cell preparations as mentioned before, can be obtained for example according to the methods set forth in US Patent No. 6,060,051. In particular the preparation can be obtained by precipitating the metabolites as contained in the preparations mentioned before by using organic solvents like ethyl acetate and subsequent redissolving of the precipitated metabolites in an appropriate solvent. The metabolites may subsequently be purified by size exclusion filtration that groups metabolites into different fractions based on molecular weight cut-off. The preparation containing an effective mixture of metabolites of the current invention preferably comprises at least five, more preferably at least 6, 7, 8, 9, 10 or 12, in particular all metabolites of the strains of the invention. The content of metabolites of the strain DSM 32315 is depicted in Table 5.1. The metabolites possess preferably a molecular weight of between 400 and 4000 Dalton, more preferably of between 500 and 3500 Dalton.
Preferably according to the invention always an effective amount of the strains and/or preparations and/or compositions of the current invention is used in the embodiments of the current invention. The term "effective amount" refers to an amount which effects at least one beneficial effect to an animal and/or to the environment, in particular with respect to the features as already mentioned before, in comparison to an animal that has not been administered the strains and/or preparations and/or compositions of the current invention, but besides that has been administered the same diet (including feed and other compounds).
In case of therapeutic applications preferably a therapeutic amount of the strains and/or preparations and/or compositions of the current invention is used. The term "therapeutic amount" refers to an amount sufficient to ameliorate, reverse or prevent a disease state in an animal. Optimal dosage levels for various animals can easily be determined by those skilled in the art, by evaluating, among other things, the composition's ability to (i) inhibit or reduce pathogenic bacteria in the gut at various doses, (ii) increase or maintain levels of beneficial bacteria and /or (iii) enhance animal health at various doses. Working Examples
Example 1. Strain characteristics relevant to survival in the gastrointestinal tract.
Bacillus subtilis strains were screened from various environmental samples in order to obtain a superior strain as animal direct-fed microbial / probiotic. As the strain is intended to reach its full potential in the intestine of the target animal, the strain was pre-screened to withstand various environmental and gut related conditions. Strain spores were generated (Nicholson and Setlow 1990), washed and incubated at 80 °C for 20 minutes (pasteurization), then titrated in logarithmic / 1 in 10 dilutions using veal infusion broth agar (VI, Difco™, no. 234420, Becton Dickinson GmbH, Heidelberg, Germany). The second highest dilution prior to no growth was stored at -80 °C and used as standardized starting point for all further assessments from spore state. To simulate gastric passage (Argenzio 2004a; Trampel and Duke 2004), survival of acid exposure was assessed based on Larsen et al. (2014). Growth of vegetative cells was furthermore assessed at low pH indicating growth under stomach/proventriculus and gizzard conditions, as well as in presence of up to 4 mM bile (B8631, CAS 8008-63-8, Sigma-Aldrich) at pH 7 in order to confirm strain growth at the proximal part of the small intestine right after clearance of the stomach or gizzard (Argenzio 2004b; Trampel and Duke 2004). ) Strain fitness in the anaerobe intestine (Argenzio 2004b; Trampel and Duke 2004) was assessed by inoculating standardized spore solutions under anaerobic conditions (AnaeroPak™, Thermo Fisher Scientific) in VI medium supplemented with 2.5 mM KNO3 (Glaser et al. 1995). Furthermore was the anaerobe proteolytic and cellulytic activity of strains assessed on VI agar plates supplemented with 1% skim milk powder (70166, Sigma-Aldrich) or 0.1% water insoluble AZCL-HE cellulose (I-AZCEL, Megazyme
International, Bray, Ireland). Osmotic stress, as also found in the gut (Argenzio 2004b; Trampel and Duke 2004), was assessed by determining growth on VI agar with addition of 5% NaCl (den Besten et al. 2009). Finally, spore heat stability was assessed to determine pelleting stability by exposing spores to 99 °C for 20 min (Palop et al. 1996) and subsequent inoculation on VI agar.
Bacillus subtilis strain DSM 32315 survived simulated gastric passage, growth of strain DSM 32315 was observed starting at pH 6. Strain DSM 32315 grew anaerobically and was able to degrade water- insoluble cellulose and protein under anaerobic conditions. Strain DSM 32315 was able to grow in presence of 2 and 4 mM bile, as well as in presence of 5% NaCl. Strain DSM 32315 reached an average spore count of 8.42 x 10s CFU/mL, and spores of strain DSM 32315 were viable after exposure to 99°C for 20 min.
References:
Argenzio, R. A. (2004a). Secretion of the Stomach and Accessory Glands, p. 405 - 418. In: Reece, W. O. (ed.), Duke's Physiology of Domestic Animals; Twelfth Edition, Chapter 25; Cornell University Press, Ithaca, New York, USA.
Argenzio, R. A. (2004b). Digestive and Absorptive Functions of the Intestines, p. 419 - 437. In: Reece, W. O. (ed.), Duke's Physiology of Domestic Animals; Twelfth Edition, Chapter 26; Cornell University Press, Ithaca, New York, USA.
Dawson, R. M. C; Elliot, D. C; Elliot, W. H.; Jones, K. M. (1986). Data for Biochemical Research; 3rd edition, Oxford Science Publishing, United Kingdom.
Den Besten HMW, Mols M, Moezelaar R, Zwietering MH, Abee T. (2009). Phenotypic and transcriptomic analyses of mildly and severely salt-stressed Bacillus cereus ATCC 14579 cells. Appl Environ Microbiol. 75:4111-9.
Glaser, P., A. Danchin, F. Kunst, P. Zuber, and M. M. Nakano. (1995). Identification and isolation of a gene required for nitrate assimilation and anaerobic growth of Bacillus subtilis. J. Bacteriol. 177: 1112- 1115 Nicholson W. L., Setlow P. Sporulation, germination and outgrowth. In: Harwood C R, Cutting S M, editors. Molecular biological methods for Bacillus. Chichester, England: John Wiley & Sons Ltd.; 1990. pp. 27-74.
Palop, A., Raso, J., Pagan, R., Condon, S. and Sala, F.J. (1996). Influence of pH on heat resistance of Bacillus licheniformis in buffer and homogenized foods. International Journal of Food Microbiology 29, 1-10.
Trampel, D. W. and Duke, G. E. (2004). Avian Digestion, p. 488 - 500. In: Reece, W. O. (ed.), Duke's Physiology of Domestic Animals; Twelfth Edition, Chapter 29; Cornell University Press, Ithaca, New York, USA.
Example 2. Comparative strain performance relative to state of the art direct-fed microbial (DFM) / probiotic for animal nutrition - quantitative assessment of bile tolerance.
In order to assess the competitiveness of the Bacillus subtilis strain DSM 32315 selected from example 1, benchmarked analysis was performed using commercially available Bacillus subtilis strains DSM 17299 and DSM 5750. As both strains were identical as per every test performed, data in this and all following examples used strain DSM 17299 as reference. Readiness of strains to perform in the proximal small intestine in presence of bile at neutral pH right after gastric passage (Argenzio 2004b; Trampel and Duke 2004) was determined by strain growth in VIB media with addition 2 mM bile. Overnight culture with 50 uL candidate strain cell suspension and 10 mL VIB in 100 mL conical flask was incubated at 37 °C and 200 rpm, then approximately 50 uL of overnight culture was transferred to 100 well honeycomb plates (Oy Growth Curves Ab Ltd, former Thermo Labsystems, Helsinky, Finland) with 1 mL VIB at pH 7 with 2 mM bile in order to obtain OD 0.2 per mL. Strain specific growth at 37 °C and 200 rpm was observed for 48 h with OD determined every 15 min using
Bioscreeen C MBR with BioLink software package (Oy Growth Curves Ab Ltd). Averaged triplicate blank OD read of broth with bile only (blanks) were subtracted per culture at each time point before area under the curve (AUC) was calculated. Quantitative assessment for each strain was compared as area under the curve between 0-5 h (AUC5, in OD x time in h), area under the curve between 0-10 h (AUC 10 in OD x time in h), and time until strains reached its maximum optical density (Tmax in h). Statistical analysis was performed using one-way ANOVA procedure of MiniTab ® 16 Statistical Software (Minitab Inc., State College, PA, USA). Results can be found in Table 2.1.
Table 2.1. Growth of Bacillus subtilis strain DSM 32315 and benchmark strain DSM 17299 in presence of2 mM bile.
Strain ID AUC5 AUC 10 Tmax
DSM 32315 0.884 A 1.730 A 17.5 B
DSM 17299 0.371 B 1.381 B 27.4 A
P-value P < 0.001 P = 0.001 P < 0.001
SEM 0.013 0.020 0.2 AUC5, area under the curve between time point 0 and 5 h in optical density x h; AUC10, area under the curve between time point 0 and 10 h in optical density x h; Tmax, time in h until maximum optical density was reached; SEM, pooled standard error of the mean; A'B means that do not share a letter are significantly different.
In direct comparison, strain DSM 32315 reached its maximum OD in presence of 2 mM bile 10 h faster than the benchmark Bacillus subtilis strain DSM 17299. In addition, strain DSM 32315 grew 2.4 fold faster during the first 5 hours, and 1.3 fold faster during the first 10 h of the test, compared to growth of benchmark strain DSM 17299, respectively.
References:
Argenzio, R. A. (2004b). Digestive and Absorptive Functions of the Intestines, p. 419 - 437. In: Reece, W. O. (ed.), Duke's Physiology of Domestic Animals; Twelfth Edition, Chapter 26; Cornell University Press, Ithaca, New York, USA.
Trampel, D. W. and Duke, G. E. (2004). Avian Digestion, p. 488 - 500. In: Reece, W. O. (ed.), Duke's Physiology of Domestic Animals; Twelfth Edition, Chapter 29; Cornell University Press, Ithaca, New York, USA.
Example 3. Comparative strain performance relative to state of the art direct-fed microbial (DFM) / probiotic for animal nutrition - growth in presence of short chain fatty acids (SCFA).
Comparative growth of strains DSM 32142 and DSM 17299 was assessed in presence of short chain fatty acids as those are observed in the gut with increasing importance towards the large intestine (Argenzio 2004b; Trampel and Duke 2004). Tests were initiated using standardized spore solution as described in example 1 testing aerobe growth in VI medium at 37°C and pH 6, read-out parameter was growth versus no growth. For this test, VI medium was adjusted to pH 6 using Mcllvaine buffer (Palop et al. 1996) and subsequently supplemented with 0,05 % acetic acid (HA, 537020, CAS 64-19-7, Sigma-Aldrich), 0,05 % propionic acid (HP, P1386, CAS 79-09-4, Sigma-Aldrich) or 0,2 % lactic acid (HL, W261106, CAS 50-21-5, Sigma-Aldrich). Results can be found in Table 3.1. Table 3.1. Assessment of growth of Bacillus subtilis strains DSM 32315 and benchmark strain DSM 17299 in presence of short chain fatty acids at pH6.
Figure imgf000020_0001
Bacillus subtilis strain DSM 32142 was able to grow at pH 6 in the presence of acetic, propionic and lactic acid, whereas strain DSM 17299 was unable to grow from spore stage under these conditions. References: Argenzio, R. A. (2004b). Digestive and Absorptive Functions of the Intestines, p. 419 - 437. In: Reece, W. O. (ed.), Duke's Physiology of Domestic Animals; Twelfth Edition, Chapter 26; Cornell University Press, Ithaca, New York, USA.
Palop, A., Raso, J., Pagan, R., Condon, S. and Sala, FJ. (1996). Influence of pH on heat resistance of Bacillus licheniformis in buffer and homogenized foods. International Journal of Food Microbiology 29, 1-10.
Trampel, D. W. and Duke, G. E. (2004). Avian Digestion, p. 488 - 500. In: Reece, W. O. (ed.), Duke's Physiology of Domestic Animals; Twelfth Edition, Chapter 29; Cornell University Press, Ithaca, New York, USA.
Example 4. Comparative strain performance relative to state of the art direct-fed microbial (DFM) / probiotic for animal nutrition - quantitative assessment of enzymatic activity.
Similar to test conducted in Example 2, strains DSM 32315 and DSM 17299 were compared evaluating the respective carbohydrate degradation activity. Cellulase and Xylanase activity were determined as described in Larsen et al. (2014). Analysis was performed in three independent runs, then averaged as milliunits per microliter solution, statistical analysis was performed using one-way ANOVA procedure of MiniTab ® 16 Statistical Software (Minitab Inc., State College, PA, USA). Results can be found in Table 4.1.
Table 4.1. Cellulase and xylanase activity of strains DSM 32315 and DSM 17299.
Figure imgf000022_0001
SEM, pooled standard error of the mean; Α' B means that do not share a letter are significantly different. In direct comparison, strain DSM 32315 demonstrated significant 7.5 fold increased cellulase and 2.1 fold increased xylanase activity comparing to benchmark strain DSM 17299.
Reference:
Larsen, N., Thorsen, L., Kpikpi, E. N., Stuer-Lauridsen, B., Cantor, M. D., Nielsen, B., Brockmann, E., Derkx, E. M. F. and Jespersen, L. (2014). Characterization of Bacillus spp. strains for use as probiotic additives in pig feed. Applied microbiology and biotechnology, 98(3), 1105-1118.
Example 5. Comparative strain performance relative to state of the art direct-fed microbial (DFM) / probiotic for animal nutrition - expression of metabolites and pathogen inhibition.
Similar to tests conducted in Example 2, strains DSM 32315 and benchmark strain DSM 17299 were compared evaluating the respective number of metabolites expressed and pathogens inhibited in the respective media. For metabolite expression analysis, starter cultures were grown and tests performed as described in Scholz et al. (2011). From 10 mL Luria Bertami broth (LB, Thermo Fisher Scientific) culture grown for 24 h at 37°C and 160 rpm in 100 mL flask, 100 uL were transferred to main culture. Main culture was grown either in 10 mL LB containing 0.2 mL / L KellyT trace metal solution (LBKelly, Scholz et al. 2011), or 10 mL Trypticase Soy Broth (Oxoid, Thermo Fisher Scientific) with 0.6% yeast extract (Y1625, CAS 8013-1-2, Sigma-Aldrich; resulting broth abbreviated TSBYE), both for 24 h at 37°C at 160 rpm in 100 mL flask. Of the main culture, 4 mL were combined with 2 mL n- Butanol in 15 mL test tube, vortexed for 3 min, then sonicated for 15 min. After centrifugation for 1 min at 5000 rpm, organic phase was transferred, vacuum dried and analyzed using High-performance liquid chromatography - electrospray ionization mass spectrometry (HPLC-ESI-MS; Chen et al. 2006). Every sample was measured in two different modes, negative and positive mode, and mass spectra were acquired. Resulting peaks as similarly reported in Teo and Tan (2005) were converted to molecular mass in Da. Results for comparison can be found in Table 5.1. Table 5.1. Comparison of metabolites expressed by strains DSM 32315 and DSM 17299, respectively
Molecular Mass -> 504 Da 529 Da 571 Da 967 Da 994 Da 1008 Da 1022 Da 1036 Da 1050 Da 1053 Da 1463 Da 1475 Da 1477 Da 1505 Da 3398 Da 3401 Da 3419 Da
DSM 32142 LBKelly yes n/d n/d n/d yes yes yes yes traces n/d Yes Yes Yes Yes n/d yes yes
TSBYE n/d Yes yes yes n/d yes yes yes traces n/d n/d n/d n/d n/d n/d n/d n/d
Combined Yes Yes Yes Yes Yes Yes Yes Yes traces Yes Yes Yes Yes Yes Yes
DSM 17299 LBKel ly n/d n/d n/d n/d n/d traces traces traces traces n/d n/d n/d n/d n/d yes n/d n/d
TSBYE n/d n/d n/d yes n/d n/d n/d n/d n/d yes n/d n/d n/d n/d n/d n/d n/d
Combined yes traces traces traces traces
In addition, Clostridium perfringens inhibition via Bacillus subtilis bacteriocin production, as part of metabolites from table 5.1. but not closer investigated, was assessed using well diffusion antagonismus test (Parente et al. 1995). Four pathogenic C. perfringens candidates were tested being C. perfringens type strain ATCC 13124 from Teo and Tan (2005), as well as three pathogenic C. perfringens field isolates from poultry and swine, obtained from University of Leipzig, Faculty of Veterinary Medicine, Department of Bacteriology and Mycology, Prof. Dr. Christoph Baums, Potsdam, Germany. The C. perfringens type A-strains from Leipzig describe as follows: Strains 2300-1-17 and 2300-1-18 were isolated from necrotic enteritis positive chicken digestive tract. Both strains produce a-toxin, strain 2300-1-17 also expressing NetB toxin (Sawa et al. 2013; Uzal et al. 2014,) whereas strain 2300-1-18 tested positive for β2 -toxin (Allaart et al. 2012). Strain 2300-1-19 was isolated from digestive tract of a scouring piglet exhibiting symptoms of Clostridial type A enteritis (Songer and Uzal 2005). Growth conditions and media were described by Teo and Tan (2005). In brief, Bacillus strains were grown in 10 mL TSBYE and LBKelly starter culture for 24 h at 37°C and 160 rpm in 100 mL flask in 5% C02 atmosphere, respectively. Clostridium perfringens starter cultures were cultivated anaerobically (AnaeroPak™, Thermo Fischer Scientific) in fluid thioglycolate broth (FTB, Becton Dickenson) for 24 h at 37°C and 160 rpm in 100 mL flask, then spread with sterile cotton swab agar plates (TSBYE with 1% agar, short TSAYE). Inoculated TSAYE plates were then incubated anaerobically overnight at 37°C in order to obtain lawn of C. perfringens. After overnight growth, three 9 mm diameter wells were cut into the agar with lawn, 1st well was used as non-inoculated control without culture, 2nd well was inoculated with 100 uL not- C. perfringens-inhibiting Bacillus strain (B. cereus var. toyoi, NCIMB
40112), the 3rd well was inoculated with 100 uL of Bacillus subtilis DSM 32315 or DSM 17299 starter culture. After 24 h incubation at 37°C, zone of clearance in mm was determined measuring from the edge of the cut well to the border of the cleared lawn, each colony was measured twice (horizontally, vertically), then averaged. For each Bacillus subtilis antagonism test and media, analysis was performed in duplicate plate runs. Statistical analysis was performed using one-way ANOVA procedure of MiniTab ® 16 Statistical Software (Minitab Inc., State College, PA, USA), results can be found in Table 5.2. for pathogen inhibition (strains grown in LBKelly), in Table 5.3 for pathogen inhibition (strains grown in TSBYE).
Table 5.2. Comparison of Bacillus subtilis DSM 32315 and DSM 17299 inhibitory capacity of pathogenic C. perfringens well diffusion antagonism assay (strains grown in LBKelly), values in mm clearance of pathogen.
Figure imgf000025_0001
Table 5.3. Comparison of Bacillus subtilis DSM 32315 and DSM 17299 inhibitory capacity of pathogenic C. perfringens well diffusion antagonism assay (strains grown in TSBYE), values in mm clearance of pathogen.
Figure imgf000025_0002
References:
Allaart, J. G., de Bruijn, N. D., van Asten, A. J., Fabri, T. H., and Grone, A. (2012). NetB-producing and beta2 -producing Clostridium perfringens associated with subclinical necrotic enteritis in laying hens in the Netherlands. Avian Pathol., 41 :541-546
Chen, X. H., Vater, J., Piel, J., Franke, P., Scholz, R., Schneider, K., Koumoutsi, A., Hitzeroth, G.,
Grammel, N., Strittmatter, A. W., Gottschalk, G., Sussmuth, R. and Borriss, R. (2006). Structural and functional characterization of three polyketide synthase gene clusters in Bacillus amyloliquefaciens FZB 42. Journal of bacteriology, 188(11), 4024-4036.
Parente, E., Brienza, C, Moles, M., & Ricciardi, A. (1995). A comparison of methods for the measurement of bacteriocin activity. Journal of microbiological methods, 22(1), 95-108. Sawa, G. S., Femandes da Costa, S. P., Bokori-Brown, M., Naylor, C. E., Cole, A. R., Moss, D. S., Titball, R- W., and Basak, A. 2013. Molecular architecture and functional analysis of NetB, a pore- forming toxin from Clostridium perfringens. J Biol. Chem., 288: 3512-3522.
Scholz, R., Molohon, K. J., Nachtigall, J., Vater, J., Markley, A. L., Sussmuth, R. D., Mitchell, D. A. and Borriss, R. (2011). Plantazolicin, a novel microcin B17/streptolysin S-like natural product from Bacillus amyloliquefaciens FZB42. Journal of bacteriology, 193(1), 215-224.
Songer, J. G., and Uzal, F. A. (2005). Clostridial enteric infections in pigs. Journal of veterinary diagnostic investigation, 17(6), 528-536.
Teo, A. Y.-L. and Tan, H.-M. (2005). Inhibition of Clostridium perfringens by a novel strain of Bacillus subtilis from the gastrointestinal tracts of healthy chickens. Appl. Environm. Microbiol., 71 :4185-90. Uzal, F. A., Freedman, J. C, Shrestha, A., Theoret, J. R., Garcia J., Awad, M. M., Adams, V., Moore, R. J., Rood, J. I., and McClane, B. A. (2014). Towards an understanding of the role of Clostridium perfringens toxins in human and animal disease. Future Microbiol., 9:361-377 Example 6. Comparison of performance of broilers reared in India fed a novel Bacillus subtilis, a competitor Bacillus subtilis product or an antibiotic growth promoter
A broiler growth performance study was conducted, using as-hatched Vencobb 400 (Venkateshwara Hatcheries Pvt. Ltd, India) day old chicks in a floor pens with used litter. Four dietary treatments were randomly assigned, with twelve replicate pens per treatment containing 25 birds per pen. Birds were fed with one of the dietary treatments in three phases consisting of starter (1-14 days), grower (15-28 days) and finisher (29-42 days) phases. The basal diet was mainly based on corn-soybean meal (Table 6.1) containing 500g/MT of dinotolmide to control coccidiosis. The basal diet also included 4% meat and bone meal (MBM), as additional challenge as MBM is a predisposing factor for development of necrotic enteritis caused by Clostridium perfringens in broiler chickens (M'Sadeqa et al. 2015). Four treatments were mainly based on corn-soybean meal (Table 6.1) and included; 1. Basal control
(Control), 2. Control + 50 g of Bacitracin Methylene Disalicyclate/MT of feed (BMD), 3. Control + a competitor product with Bacillus subtilis strain at 500 g/MT of feed with 1.6* 109 cfu/g (DSM 17299), 4. Control + a Bacillus subtilis strain DSM 32315 at 250 g/MT containing 2.0* 109 cfu/g (DSM 32315) Experimental treatments were fed ad libitum in mash form from 1-42 days of age. Statistical analysis was performed using one-way ANOVA procedure and LSD post-test analysis with SAS vs9.4 (SAS Institute Inc., USA). The results of the treatments on body weight, feed conversion ratio and mortality are reported in Table 6.2. Table 6.1. Ingredient and nutrient composition of basal diet.
Ingredients, % Starter (1-14 d) Grower (15-28 d) Finisher (29-42 d)
Corn 53.98 62.27 64.54
Soybean meal, 48% CP 36.09 27.64 24.63
Meat and bone meal 4.00 4.00 4.00
Soybean oil 2.46 2.60 3.60
Dicalcium phosphate 22 1.48 1.51 1.53
Calcium carbonate 0.39 0.45 0.16
Premix (including vit-min mix) 0.65 0.65 0.65
Sodium chloride 0.28 0.29 0.29
Sodium bicarbonate 0.10 0.10 0.10
Choline chloride 50 0.10 0.10 0.10
DL-Methionine 0.29 0.23 0.22
L-Lysine HC1 0.12 0.13 0.14
L-Threonine 0.05 0.04 0.05
Nutrient composition
ME, kcal/kg 2950 3050 3150
CP, % 23.50 20.08 18.83
Ca 1.00 1.00 1.00
Available P 0.45 0.45 0.45
Lys 1.36 1.14 1.06
Met 0.63 0.53 0.50
M+C 0.99 0.85 0.80
Thr 0.92 0.78 0.74
Trp 0.27 0.22 0.20
Arg 1.59 1.33 1.23
He 0.97 0.81 0.75
Leu 1.93 1.70 1.61
Val 1.08 0.92 0.86 Table 6.2. Animal performance between days 0 and 42, with and without diet supplementation with B. subtilis based feed additive or antibiotic growth promoter.
1 - 21 d l - 42 d
Treatment BW, g FCR, g/g BW, g FCR, g/g
1. Control 621.8 1.49 2278.2 1.76
2. BMD 649.4 1.45 2321.4 1.74
3. DSM 17299 631.4 1.49 2281.8 1.76
4. DSM 32315 635.0 1.48 2309.2 1.73
Difference 13.2 -0.01 31.0 -0.03
Relative % 2.1% -0.7% 1.4% -1.7%
BW, average bird body weight in specified time period; FCR, feed conversion ratio calculated as feed to gain in specified time period; Control, no additives in basal diet; BMD, treatment with addition of bacitracin methylene disalicylate to basal diet; DSM 17299, treatment with addition of DSM 17299 to basal diet; DSM 32315, treatment with addition of strain DSM 32315 to basal diet; Difference, the numeric difference observed when DSM 32315 was compared to control; Relative %, the difference between DSM 32315 and control as a percent change from control.
In the starter and grower period from 1-21 days DSM 32315 improved the FCR of broilers by 0.7% compared to the control. Body weight at 21 days was also improved by 2.1 % when DSM 32315 was fed to broilers compared to the control. While these improvements were not to the extent of that observed when the very potent antibiotic growth promoter BMD was utilized, DSM 32315 did improve broiler performance in this period to a greater extent than DSM 17299.
Throughout the entire grow out period of broilers DSM 32315 was able to improve both body weight and feed conversion by 1.4% and -1.7% respectively. These improvements were again greater than those observed when the competitor product DSM 17299 was used. While day 42 body weight was still better in the antibiotic growth promoter group BMD, DSM 32315 treatment was able to reduce the FCR by an additional 0.01 (0.6%) compared to the BMD supplemented treatment group.
Overall, these results suggest that birds supplemented with DSM 32315 performed better than those fed a control or DSM 17299 and in at least some parameters was able to perform similarly to a highly effective antibiotic growth promoter.
References.
M'Sadeqa, S., Wua S., Swicka, R.A. and M. Chocta (2015). Towards the control of necrotic enteritis in broiler chickens with in- feed antibiotics phasing-out worldwide. Animal Nutrition. 1 : 1-11. Example 7. Comparison of performance of broilers reared in Thailand fed a novel Bacillus subtilis, a competitor Bacillus subtilis product or an antibiotic growth promoter.
A broiler growth performance study was conducted with male, Ross 308 (Aviagen Asia, Thailand) day old chicks placed in floor pens with used litter. There were four dietary treatments, 16 replicate pens per treatment and 12 birds per pen. Birds were fed with one of the dietary treatments in three phases consisting of starter (1-14 days), grower (15-28 days) and finisher (29-42 days) phases. The basal diet was mainly based on corn-soybean meal (Table 7.1) containing 60g salinomycin/MT of feed to control coccidiosis. The basal diet also included 5% corn dried distiller's grains with solubles (DDGS), as the addition of DGGS, especially in starter diets, can reduce the rate of broiler growth (Lumpkins et al. 2004) and is a predisposing factor for development of necrotic enteritis caused by Clostridium perfringens in broiler chickens (Macklin et al. 2011). The four dietary treatments included; 1. Basal control (Control), 2. Control + 20 g of Zinc Bacitracin /MT of feed (ZnB), 3. Control + a competitor product with Bacillus subtilis strain at 500 g/MT of feed with 1.6* 109 cfu/g (DSM 17299), 4. Control + a Bacillus subtilis strain DSM 32315 at 250 g/MT containing 2.0* 109 cfu/g (DSM 32315). The basal diet. Statistical analysis was performed using one-way ANOVA procedure and LSD post-test analysis with SAS vs9.4 (SAS Institute Inc., USA). Animal growth performance 0-42 days can be found in Table 7.2.
Table 7.1. Ingredient and nutrient composition of basal diet.
Ingredients, % Starter (1-14 d) Grower (15-28 d) Finisher (29 »-42 d)
Corn 45.39 54.62 57.84
Soybean meal, 44% CP 40.00 30.82 27.00
Corn DDGS 5.00 5.00 5.00
Soybean oil 4.64 4.61 5.44
Monocalcium phosphate 1.59 1.61 1.63
Calcium carbonate 1.71 1.78 1.51
Premix (including Vit-min mix) 0.65 0.65 0.65
Sodium chloride 0.31 0.31 0.31
Sodium bicarbonate 0.10 0.10 0.10
Choline chloride 50 0.10 0.10 0.10
DL-Methionine 0.28 0.22 0.21
L-Lysine HC1 0.14 0.15 0.17
L-Threonine 0.04 0.03 0.05
Nutrient composition
ME, kcal/kg 2950 3050 3150
CP, % 23.01 19.63 18.22
Ca 1.00 1.00 0.90
Available P 0.45 0.45 0.45
Lys 1.35 1.12 1.04
Met 0.62 0.52 0.50
M+C 0.98 0.84 0.80
Thr 0.92 0.78 0.74
Trp 0.28 0.23 0.21
Arg 1.52 1.26 1.15 lie 0.98 0.81 0.75
Leu 1.94 1.72 1.62
Val 1.08 0.92 0.85 Table 7.2. Animal performance between days 0 and 42, with and without diet supplementation with B. subtilis based feed additive or antibiotic growth promoter.
l - 42 d
Treatment BW, g FCR, g/g Mortality %
1. Control 2845.0 1.83 4.17
2. ZnB 2988.0 1.78 1.67
3. DSM 17299 2926.6 1.79 2.56
4. DSM 32315 3033.8 1.78 1.92
Difference 188.8 -0.05 -2.25
Relative % 6.9% -2.7%
BW, average bird body weight in specified time period; FCR, feed conversion ratio calculated as feed to gain in specified time period and adjusted for mortalities; Control, no additives in basal diet; ZnB, treatment with addition of zinc bacitracin; DSM 17299, treatment with addition of DSM 17299 to basal diet; DSM 32315, treatment with addition of strain DSM 32315 to basal diet; Difference, the numeric difference observed when DSM 32315 was compared to control; Relative %, the difference between DSM 32315 and control as a percent change from control.
During the entire grow-out period between 1 and 42 days, treatment with DSM 32315 was able to reduce the FCR by 2.7%. While this effect was also observed with the other treatment groups, BMD and DSM 17299, DSM 32315 treatment also resulted in the heaviest final body weight with a 6.9% increase from the control. Additionally, DSM 17299 was able to reduce the mortality of birds by 2.25% compared to untreated controls and by 0.64% compared to DSM 17299.
These results indicate that while all treatments were able to improve the feed conversion over the whole period, that supplementation with DSM 32315 resulted in the heaviest final body weight of birds and a noticeable reduction in mortality.
References
Lumpkins, B. S., Batal, A. B., & Dale, N. M. (2004). Evaluation of distillers dried grains with solubles as a feed ingredient for broilers. Poultry Science, 83(11), 1891-1896.
Macklin, K. S., Rose, L. N., and Dozier III, W. A. (2011). The effects of different levels of DDGS on necrotic enteritis development in broiler chickens. In Western Poultry Disease Conference, p. 123. Example 8. Comparison of performance of broilers with and without dietary inclusion of a novel Bacillus subtilis when undergoing an induced Necrotic Enteritis challenge.
A necrotic enteritis challenge study was conducted, using male Ross 308 (Aviagen) day old chicks in floor pens. Three dietary treatments were randomly assigned, with eleven replicate pens per treatment containing 14 birds per pen. Birds were fed with one of the dietary treatments in three phases consisting of starter (1-11 days), grower (12-25 days) and finisher (26-35 days) phases. The basal diet was mainly based on corn-soybean meal (Table 8.1). The starter diet was prepared as 2 mm crumbled pellets and the grower and finisher diets as 4 mm pellets. The three treatments included; 1. Basal control (Control), 2. Positive Control + Narasin Coccidiostat (Monteban® G100, Elanco USA) 650g/MT of feed
(Narasin), 3. Control + a Bacillus subtilis strain DSM 32315 at 250 g/MT containing 2.0* 109 cfu/g (DSM 32315). Experimental treatments were fed ad libitum from 1-35 days of age.
Necrotic enteritis is a disease of chickens caused by a predisposing Eimeria infection with a synergistic Clostridium perfringens infection that usually occurs in 3-4 week old broilers (Timbermont et al. 201 1). The Necrotic Enteritis challenge was induced in two parts; at 12 days of age each bird received an oral inoculation of 5000 E. maxima oocytes and at 16 days of age each bird received 300μ1 of an overnight culture of a field strain of Clostridium perfringens that was originally isolated from ileal contents of broiler chicks suffering from necrotic enteritis. The results of the treatments on body weight, feed conversion ratio and mortality are reported in Table 8.2. The mortality is reported from day 1 1-35 to control for early bird losses due to chick quality that are not relevant to the disease challenge induced. As footpad dermatitis has been connected to wet litter (Taira et al. 2014) and wet litter can be caused by gut health issues like necrotic enteritis (Timbermont et al. 201 1), footpad lesion scores were also measured. The footpads were scored from sampled birds for pododermatitis (i.e., foodpad disease) using scale from 0 (representing no evidence of pododermatitis) to 4 (severe pododermatitis) based on the Welfare Quality 2009 (Rushen et al. 201 1). The results of the treatments on footpad lesion scores is reported in Table 8.3. Specific bacterial groups (Bacillus spp. and Clostridium perfringens) were enumerated in ileal and caecal digesta samples from days 1 1, 18 and 35. Extracted DNA from the digesta samples was used in a quantitative PCR with primers specific to the species of interest. The results of the treatments on the molecular enumeration of bacterial groups (Bacillus spp. and
Clostridium perfringens) at days 11, 18 and 35 is reported in Tables 8.4, 8.5 and 8.6 respectively.
Table 8.1 Ingredient and nutrient composition of basal diet.
Ingredients, % Starter (1-11 d) Grower (12-25 d) Finisher (26-35 d)
Corn 52.15 57.12 61.93
Soybean meal, 48% CP 40.06 35.45 30.33
Soybean oil 3.28 3.68 4.12
Monocalcium phosphate 1.76 1.47 1.31
Premix of trace elements and
0.40 0.40 0.40
vitamins
Calcium carbonate 1.40 1.18 1.11
Sodium chloride 0.37 0.37 0.37
Choline chloride (60%) 0.09 0.09 0.09
DL-Methionine 0.30 0.23 0.23
L-Lysine HCI 0.13 0.09 0.08
L-Threonine 0.04 0.03 0.02
Nutrient composition
ME, kcal/kg 2950 3025 3100
CP, % 22.96 21.50 19.50
Calcium 1.00 0.85 0.78
Available Phosphorous 0.50 0.43 0.39
Lysine 1.35 1.19 1.10
Methionine 0.61 0.54 0.52
Methionine+Cystine 0.97 0.88 0.84
Threonine 0.92 0.82 0.76
Tryptophan 0.28 0.26 0.23
Arginine 1.55 1.45 1.29
Isoleucine 0.98 0.92 0.82
Valine 1.07 1.01 0.91
d, day; CP, crude protein; ME, metabolizable energy; kcal, kilocalories; kg, kilograms
Table 8.2. Animal performance between days 0 and 35, with and without diet supplementation with B. subtilis based feed additive or Narasin.
1 - 35 days
Treatment BW, g FCR, g/g aFCR, g/g Mortality, %
1. Control 2802.0 1.605 1.505
2. Narasin 2778.4 1.431 1.425 3. DSM 32315 2845.5 1.493 1.456 3.9
Difference +43.5 -0.112 -0.049 ^5
Relative % +1.55 +6.98 +3.26
BW, average bird body weight; FCR, feed conversion ratio calculated as feed to gain in specified time period; aFCR, feed conversion ratio calculated as feed to gain and adjusted for mortalities in specified time period; Mortality, the mortality from day 11-35 as a percentage of the pen population; Control, no additives in basal diet; Narasin, treatment with addition of narasin coccidiostat to basal diet; DSM 32315, treatment with addition of the novel Bacillus subtilis strain DSM 32315 to basal diet; Difference, the numeric difference observed when DSM 32315 was compared to control; Relative %, the difference between DSM 32315 and control as a percent change from control.
Table 8.3. Footpad lesion score, with and without diet supplementation with fi. subtilis based feed additive or Narasin.
Treatment Footpad Lesion Score (0-4)
1. Control 2.29
2. Narasin 0.41
3. DSM 32315 1.77
Difference -0.52
Relative % -22.7%
Control, no additives in basal diet; Narasin, treatment with addition of narasin coccidiostat to basal diet; DSM 32315, treatment with addition of the novel Bacillus subtilis strain DSM 32315 to basal diet; Difference, the numeric difference observed when DSM 32315 was compared to control; Relative %, the difference between DSM 32315 and control as a percent change from control.
Table 8.4. Molecular enumeration of Bacillus species and Clostridium perfringens in the ileum and cecum of broilers, with and without diet supplementation with B. subtilis based feed additive or Narasin at 11 days of age.
Day 11 Ileum Day 11 Cecum
Treatment C. perfringens Bacillus spp. C. perfringens Bacillus spp.
(Log10 of gene (Log10 of gene (Log10 of gene (Log10 of gene copies/g) copies/g) copies/g) copies/g)
1. Control 4.51 4.75 6.39 4.10
2. Narasin 4.18 5.68 6.38 5.24
3. DSM 32315 4.26 6.20 6.06 6.51
Difference -0.25 +1.45 -0.33 +2.41 Control, no additives in basal diet; Narasin, treatment with addition of narasin coccidiostat to basal diet; DSM 32315, treatment with addition of the novel Bacillus subtilis strain DSM 32315 to basal diet; Difference, the numeric difference observed when DSM 32315 was compared to control. Table 8.5. Molecular enumeration of Bacillus species and Clostridium perfringens in the ileum and cecum of broilers, with and without diet supplementation with B. subtilis based feed additive or Narasin at 18 days of age.
Day 18 Ileum Day 18 Cecum
Treatment C. perfringens Bacillus spp. C. perfringens Bacillus spp.
(Log10 of gene (Log10 of gene (Log10 of gene (Log10 of gene copies/g) copies/g) copies/g) copies/g)
1. Control 6.27 4.71 6.17 4.58
2. Narasin 4.60 4.94 4.87 4.54
3. DSM 32315 5.58 5.48 5.89 5.58
Difference -0.69 +0.77 -0.28 +1.00
Control, no additives in basal diet; Narasin, treatment with addition of narasin coccidiostat to basal diet; DSM 32315, treatment with addition of the novel Bacillus subtilis strain DSM 32315 to basal diet; Difference, the numeric difference observed when DSM 32315 was compared to control.
Table 8.6. Molecular enumeration of Bacillus species and Clostridium perfringens in the ileum and cecum of broilers, with and without diet supplementation with B. subtilis based feed additive or Narasin at 35 days of age.
Day 35 Ileum Day 35 Cecum
Treatment C. perfringens Bacillus spp. C. perfringens Bacillus spp.
(Log10 of gene (Log10 of gene (Log10 of gene (Log10 of gene copies/g) copies/g) copies/g) copies/g)
1. Control 5.36 4.77 6.64 5.06
2. Narasin 4.03 4.84 4.81 5.23
3. DSM 32315 4.73 6.11 5.96 6.39
Difference -0.63 +1.34 -0.68 +1.33
Control, no additives in basal diet; Narasin, treatment with addition of narasin coccidiostat to basal diet; DSM 32315, treatment with addition of the novel Bacillus subtilis strain DSM 32315 to basal diet; Difference, the numeric difference observed when DSM 32315 was compared to control.
This study clearly provides evidence to support the beneficial effects of probiotic strain DSM 32315 on the performance of broilers facing a Necrotic Enteritis health challenge. The body weight of broilers fed DSM 32315 was increased, while the feed conversion ratio and mortality corrected feed conversion ratio was reduced compared to basal controls. These findings for the probiotic strain were similar to those of the positive control, Narasin, an anti-coccidiosial additive preventing the onset of Necrotic Enteritis in this model. Footpad lesions, associated with Necrotic Enteritis, were also reduced in broilers fed diets including strain DSM 32315 compared to basal diet control. This could be due to decreased moisture and pathogens in the litter, but this was not tested in this study.
At Day 11, 18 and 35 bacterial populations were enumerated in both the ileum and cecum of birds. In the treatment group fed diets containing the Bacillus subtilis strain DSM 32315, there were consistently more Bacillus enumerated at all time points and from both tissue sites. While some changes in Bacillus were observed in the Narasin treatment group compared to the control, these findings were very subtle and not consistent across all tissues and time points as was observed for the DSM 32315 treatment group.
When the causative agent of Necrotic Enteritis, Clostridium perfringens, was enumerated the DSM 32315 treatment group consistently showed a reduction in these pathogenic counts compared to the control group. This was similar to the positive control group, in which Narasin was added to the feed to prevent the onset of Necrotic Enteritis.
The data presented from this trial provide clear evidence as to the ability of DSM 32315 to inhibit the onset of Necrotic Enteritis and prevent subsequent losses due to loss of performance, mortality or footpad lesion condemnations at slaughter.
References
Rushen J., A. Butterworth and J. C. Swanson (2011). Animal Behaviour and Well-Being Symposium: Farm animal welfare assurance: Science and application. Journal of Animal Science 89: 1219-1228
Taira K., T. Nagai, T. Obi and K. Takase (2014). Effect of Litter Moisture on the Development of Footpad Dermatitis in Broiler Chickens. J Vet Med Sci. 76(4): 583-586
Timbermont L., F. Haesebrouck, R. Ducatelle and F. Van Immerseel (2011). Necrotic enteritis in broilers: an updated review on the pathogenesis. Avian Pathol. 40(4): 341-347
Example 9. Assessment of strain tolerance to feed pellet production and feed storage.
To test the tolerance of B. subtilis DSM 32315 spores to the feed pelleting process, spores were added to a broiler grower diet (Table 9.1) that was then pelleted at 85°C. Prior to pelleting, ten replicate samples of the mixed feed were isolated for spore counts. Feed was then pelleted at 85°C and additional five replicate samples were obtained. From the pre and post-pellet samples viable spores were cultured in dilution series, counted and calculated in feed concentrations. Results of the spore counts are presented in Table 9.2.
Table 9.1. Ingredients of the broiler diet used for pellet tolerance assessment.
Figure imgf000037_0002
Table 9.2 Spore counts in feed pre- and post-pelleting.
Figure imgf000037_0003
pre-pelleting.
Spore counts post-pelleting remained within the 30% expected range from pre-pelleted feeds, signifying no significant loss of B. subtilis DSM 32315 spores during the pelleting process.
To test the stability of B. subtilis DSM 32315 spores in feed over time, spores were added to a broiler grower diet of the same formulation as previously described in Table 9.1. The feed was pelleted at 85°C and three replicates of the diet were stored in a climate controlled chamber at 40°C and 85% humidity. Spores were counted after pelleting (0 weeks in storage) as well as after 2, 4, 8 and 12 weeks of storage. Results of spore enumeration are presented in Table 9.3.
Table 9.3 Recovery of DSM 32315 spores in pelleted feed after storage in climate chamber.
Figure imgf000037_0001
% Recovery of Spores 100.0% 84.1% 97.7% 86.4% 82.6%
% Recovery of Spores, calculated as the percentage of spores counted in relation to the spores counted at 0 weeks of storage directly after pelleting.
Spore counts in pelleted feed fluctuated over time, but remained within the expected 30% range of the spore counts obtained directly after pelleting. Therefore, it can be concluded that no significant loss of B. subtilis DSM 32315 spores was observed over 12 weeks of storage.
Example 10: Well diffusion antagonism tests with respect to different pathogenic strains
A well diffusion antagonism test with 3 different pathogens, Enterococcus cecorum DSM 20683, Streptococcus gallinaceus DSM 15349 and Streptococcus suis ATCC 43765 was performed.
E. cecorum is known to cause lameness, arthritis and osteomyelitis in broilers usually caused by an inflammation of a joint and/or bone tissue. Additional E. cecorum can cause an inflammation of the pericardium [Kense et al. 2011]. DSM 20683 was isolated from caecum of a chicken.
S. gallinaceus can cause septicaemia in poultry. The gross lesions included splenomegaly, hepatomegaly, renomegaly and congestion. Multiple areas of necrosis and/ or infarction in the liver and spleen associated with valvular endocarditis were also observed [Collins et al. 2002].
S. suis is an important pathogen in pigs and one of the most important causes of bacterial mortality in piglets after weaning causing septicemia, meningitis and many other infections [Goyette-Desjardins et al. 2014]. ATCC 43765 belongs to Serological group: R; serovar 2 and was isolated from pigs.
Bacillus strains were grown in 10 mL TSBYE (30 g/1 TSB + 6 g/1 Yeast extract) or LB-Kelly (LB- Media supplemented with trace elements solution of DSMZ media 1032) for 16 h at 37°C and 200 rpm in 100 mL shaking flask. The pathogenic strains were grown under suitable conditions as liquid culture to an optical density of 595 nm of at least 1, then 100 μΐ were spread with sterile spatula on the surface of agar plates. For S. gallinaceus BHI agar plates, for E. cecorum and S. suis TSBYE agar plates are used. Three 9 mm diameter wells were cut into the dried plates. 1st well was used as non-inoculated media control without culture, 2nd well was inoculated with 100 uL not-inhibiting Bacillus strain (B. cereus var. toyoi, NCIMB 40112), the 3rd well was inoculated with 100 uL of Bacillus subtilis DSM 32315 or DSM 17299 culture. After 24 h incubation under suitable conditions at 37°C, the zone of clearance in mm was determined measuring from the edge of the cut well to the border of the cleared lawn. Each colony was measured twice (horizontally, vertically), then averaged. The results can be found in table 10.1.
Table 10.1 : Comparison of 'Bacillus subtilis DSM 32315 and DSM 17299 inhibitory capacity on pathogenic strains in well diffusion antagonism assays, values in mm clearance of pathogen. Pathogen→ E. cecorum S. gallinaceus S. suis
Probiotic I DSM 20683 DSM 15349 ATCC 43765
DSM 32315 3,8 13,5 10,9
DSM 17299 0,0 0,0 5,5
The data show that DSM 32315 is able to inhibit the growth of is. cecorum, S. gallinaceus and S. suis very effectively, in particular in comparison to DSM 17299.
References:
MJ Kense, WJM Landman (2011). Enterococcus cecorum infections in broiler breeders and their offspring: molecular epidemiology. Avian Pathology Vol. 40 , Iss. 6.
MD Collins, RA Hutson, E Falsen, E Ingana, M Bisgaard (2002). Streptococcus gallinaceus sp. nov., from chickens. International Journal of Systematic and Evolutionary Microbiology. 52: 1161-1164. G Goyette-Desjardins, J-P Auger, J Xu, M Segura, M Gottschalk (2014). Streptococcus suis, an important pig pathogen and emerging zoonotic agent— an update on the worldwide distribution based on serotyping and sequence typing. Emerg Microbes Infect. 3(6):e45.
Print Out (Original in Electronic Form)
(This sheet is not part of and does not count as a sheet of the international application)
Figure imgf000040_0001
Indications are Made All designations
FOR RECEIVING OFFICE USE ONLY -4 This form was received with the
international application: YES
(yes or no)
-4-1 Authorized officer
Wilson, Patrick Print Out (Original in Electronic Form)
(This sheet is not part of and does not count as a sheet of the international application)
FOR INTERNATIONAL BUREAU USE ONLY -5 This form was received by the
international Bureau on:
-5-1 Authorized officer

Claims

Claims
1. A Bacillus subtilis strain or a preparation thereof selected from the following group:
a) The B. subtilis strain as deposited under DSM 32315 at the DSMZ;
b) a mutant of the B. subtilis strain as deposited under DSM 32315 having all identifying characteristics of the strain DSM 32315;
c) a preparation of (a) or (b);
d) a preparation containing an effective mixture of compounds as contained in (a), (b) or (c).
2. A Bacillus subtilis mutant of DSM 32315 according to claim 1 (b), wherein the mutant has a DNA sequence identity to the strain DSM 32315 of at least 95%.
3. A Bacillus subtilis strain or a preparation thereof, wherein the B. subtilis strain exhibits the following characteristics:
a) a 16S rDNA sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 1; and/or b) a yqfD sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 2; and/or c) a gyrB sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 3.
4. A Bacillus subtilis strain or a preparation according to any of the preceding claims, wherein the B. subtilis strain exhibits the following further characteristics:
d) an rpoB sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 4; and/or e) a groEL sequence with a sequence identity of at least 99 %, preferably at least 99.5 %, above all 100 %, to the polynucleotide sequence according to SEQ ID NO: 5.
5. The B. subtilis strain according to any of the preceding claims, characterized by being able to grow anaerobically, in particular by being able to degrade water-insoluble cellulose and protein under anaerobic conditions.
6. The B. subtilis strain according to any of the preceding claims, characterized by being able to inhibit C. prefringens, in particular characterized by a pathogen clearance of at least 10 mm, more preferably at least 13 mm, in a well diffusion antagonism assay on LBKelly agar plates with respect to C. perfringens type strain ATCC 13124.
7. The B. subtilis strain according to any of the preceding claims, characterized by being able to grow in the presence of 0.05 wt.-% acetic acid, 0.05 wt.-% propionic acid and/or 0.2 wt.-% lactic acid.
8. The B. subtilis strain according to any of the preceding claims, characterized by a cellulase activity of at least 200 mU/mL, preferably at least 300 mU/mL, in particular at least 350 mU/mL, and/or by a xylanase activity of at least 15 mU/mL, preferably at least 20 mU/mL, in particular at least 25 mU/mL.
9. The B. subtilis strain according to any of the preceding claims, characterized by being able to grow in presence of 2 mM bile, preferably in presence of 4 mM bile, in particular characterized by an AUC5 performance value of at least 0.5, preferably at least 0.65, above all at least 0.8, and an AUC10 performance value of at least 1.2, preferably at least 1.4, above all at least 1.6, in presence of 2 mM bile.
10. The use of & B. subtilis strain or a preparation thereof according to any of the preceding claims as a probiotic ingredient (DFM) in feed or food products.
11. A feed- or foodstuff composition containing a B. subtilis strain or a preparation thereof
according to any one of claims 1 to 9 and at least one further feed or food ingredient, preferably selected from proteins, carbohydrates, fats, further probiotics, prebiotics, enzymes, vitamins, immune modulators, milk replacers, minerals, amino acids, coccidio stats, acid-based products, medicines, and combinations thereof.
12. A pharmaceutical composition containing a. B. subtilis strain or a preparation thereof according to any one of claims 1 to 9 and a pharmaceutically acceptable carrier.
13. A composition according to claim 11 or 12 for improving the health status, in particular the gut health status, of an animal or a human being.
14. A method of feeding an animal, in particular an avian, more preferably a chicken, characterized by applying to the animal a B. subtilis strain or a preparation according to any of claims 1 to 9 and/or a feedstuff composition according to claim 11 and/or a pharmaceutical composition according to claim 12.
15. A method of improving the health status, in particular the gut health status, of an animal or a human being, comprising administering to the animal or human being a B. subtilis strain or a preparation according to any of claims 1 to 9 or a composition according to any of claims 11 to 13.
16. A method of enhancing the health of animals and/or of improving the general physical
condition of animals and/or of improving the feed conversion rate of animals and/or of decreasing the mortality rate of animals and/or of increasing the survival rates of animals and/or of improving the weight gain of animals and/or of increasing the disease resistance of animals and/or of increasing the immune response of animals and/or of establishing or maintaining a healthy gut microflora in animals and/or of reducing the pathogen shedding through the feces of animals, wherein at least one strain and/or at least one preparation according to any of claims 1 to 9 or at least one composition according to any of claims 11 to 13 are administered to animals.
17. A method of controlling and/or avoiding detrimental environmental effects of manure or
contaminated liquids, the method comprising the step of applying to manure, contaminated liquids, litter, a pit, or a manure pond at least one strain and/or at least one preparation according to any of claims 1 to 9 and/or at least one composition according to any of claims 11 to 13.
18. A method of controlling and/or improving the quality of water or aqueous solutions, in
particular of drinking water or rearing water, the method comprising the step of applying to water or an aqueous solution at least one strain and/or at least one preparation according to any of claims 1 to 9 and/or at least one composition according to any of claims 11 to 13.
19. A method of treating and/or preventing a microbial disease of cultivated plants, comprising the step of applying to a cultivated plant at least one strain and/or at least one preparation according to any of claims 1 to 9 and/or at least one composition according to any of claims 11 to 13.
PCT/EP2017/062497 2016-05-31 2017-05-24 Bacillus subtilis strain with probiotic activity WO2017207372A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP17727530.2A EP3464558A1 (en) 2016-05-31 2017-05-24 Bacillus subtilis
MX2018014476A MX2018014476A (en) 2016-05-31 2017-05-24 Bacillus subtilis strain with probiotic activity.
BR112018074616-9A BR112018074616A2 (en) 2016-05-31 2017-05-24 bacillus subtilis strain with probiotic activity
JP2018562615A JP6991162B2 (en) 2016-05-31 2017-05-24 Bacillus subtilis strain showing probiotic activity
ZA2018/08509A ZA201808509B (en) 2016-05-31 2018-12-18 Bacillus subtilis strain with probiotic activity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP16172164 2016-05-31
EP16172164.2 2016-05-31
CN201610570955.X 2016-06-03
CN201610570955 2016-06-03
EP16196025 2016-10-27
EP16196025.7 2016-10-27

Publications (1)

Publication Number Publication Date
WO2017207372A1 true WO2017207372A1 (en) 2017-12-07

Family

ID=58994906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/062497 WO2017207372A1 (en) 2016-05-31 2017-05-24 Bacillus subtilis strain with probiotic activity

Country Status (7)

Country Link
EP (1) EP3464558A1 (en)
JP (1) JP6991162B2 (en)
CN (1) CN107446838A (en)
BR (1) BR112018074616A2 (en)
MX (1) MX2018014476A (en)
WO (1) WO2017207372A1 (en)
ZA (1) ZA201808509B (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112006A1 (en) * 2016-12-16 2018-06-21 Dupont Nutrition Biosciences Aps Bacillus-based components for inhibiting or delaying the growth of enterococcus spp. in animals
WO2019040266A1 (en) * 2017-08-23 2019-02-28 Novozymes A/S Direct fed microbials for improving the general condition and health of fish
WO2019206820A1 (en) 2018-04-23 2019-10-31 Evonik Degussa Gmbh Synbiotic compositions
WO2019235952A1 (en) * 2018-06-04 2019-12-12 Lelyak Aleksandr Ivanovich Functional drinking water
WO2020011703A1 (en) 2018-07-11 2020-01-16 Evonik Operations Gmbh Composition comprising at least one microorganism and use thereof
WO2020053271A1 (en) * 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020053274A1 (en) * 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020225020A1 (en) 2019-05-03 2020-11-12 Evonik Operations Gmbh Feed compositions containing betaine salts
US11173184B2 (en) 2016-05-31 2021-11-16 Evonik Operations Gmbh Bacillus subtilis strain with probiotic activity
US20220002667A1 (en) * 2018-11-12 2022-01-06 Dsm Ip Assets B.V. Bacillus sp. probiotic strains and mutations
RU2799354C2 (en) * 2018-04-23 2023-07-05 Эвоник Оперейшенс ГмбХ Synbiotic compositions
EP4317089A1 (en) * 2022-08-03 2024-02-07 Pruex Limited Treatment of animal waste
EP4342854A1 (en) * 2022-08-03 2024-03-27 Pruex Limited Treatment of animal waste
EP4382090A1 (en) * 2022-12-08 2024-06-12 Evonik Operations GmbH Cosmetical and pharmaceutical compositions containing bacillus strains or fermentation broths thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107699491B (en) * 2017-11-21 2021-01-15 江西省科学院微生物研究所 Sample total microorganism and protective agent and preservation method of total DNA thereof
CN108165619A (en) * 2017-12-29 2018-06-15 武汉轻工大学 The feeding prebiotic bacterial screening method of anti-chicken C.perfringens infection
CA3096300A1 (en) * 2018-05-29 2019-12-05 BiOWiSH Technologies, Inc. Compositions and methods for improving survivability of aquatic animals
KR102135195B1 (en) * 2018-10-08 2020-07-17 아주대학교산학협력단 Composition for preventing or treating behcet's diseases or herpes simplex virus infection containing tetragenococcus halophilus
CN109258537A (en) * 2018-11-20 2019-01-25 贵州工程应用技术学院 A kind of method of paddy field aquaculture Penaeus Vannmei
KR102393430B1 (en) * 2019-10-18 2022-05-02 (주)에이티바이오 Animal feed using probiotics and its manufacturing method
WO2023140321A1 (en) * 2022-01-20 2023-07-27 ホロバイオ株式会社 Novel organism breeding technique
CN114836460B (en) * 2022-05-19 2023-07-14 华南农业大学 Bacillus subtilis engineering strain for expressing micro-fungus Y and preparation and application thereof
CN117016673B (en) * 2023-10-09 2024-01-30 中国农业大学 Application of bacillus subtilis in improving intestinal flora or intestinal health or nutrient absorption of laying hens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000135096A (en) * 1998-08-28 2000-05-16 Tadayuki Imanaka Surfactant, its production and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003190993A (en) * 2001-12-27 2003-07-08 Toyo Clean Kagaku Kk Biological treatment for sludge
CN102191194B (en) * 2011-03-17 2013-06-05 四川师范大学 Bacillus subtilis and antibacterial protein thereof
KR101370942B1 (en) * 2012-04-05 2014-03-12 씨제이제일제당 (주) Novel Bacillus subtilis
FR2999191B1 (en) * 2012-12-12 2016-02-05 Lesaffre & Cie PROBIOTIC STRAINS FOR THE TREATMENT AND / OR PREVENTION OF DIARRHEA
MX359206B (en) * 2013-05-20 2018-09-19 Biowish Tech Inc Microbial-based waste water treatment compositions and methods of use thereof.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000135096A (en) * 1998-08-28 2000-05-16 Tadayuki Imanaka Surfactant, its production and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MM HOSSAIN ET AL: "Effect of Bacillus subtilis, Clostridium butyricum and Lactobacillus acidophilus endospores on growth performance, nutrient digestibility, meat quality, relative organ weight, microbial shedding and excreta noxious gas emission in broilers", VETERINARNI MEDICINA, vol. 60, no. No. 2, February 2015 (2015-02-01), CZ, pages 77 - 86, XP055319907, ISSN: 0375-8427, DOI: 10.17221/7981-VETMED *
TEO A Y-L ET AL: "Inhibition of Clostridium perfringens by a novel strain of Bacillus subtilis isolated from the gastrointestinal tracts of healthy chickens", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 8, 1 August 2005 (2005-08-01), pages 4185 - 4190, XP002375508, ISSN: 0099-2240, DOI: 10.1128/AEM.71.8.4185-4190.2005 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11173184B2 (en) 2016-05-31 2021-11-16 Evonik Operations Gmbh Bacillus subtilis strain with probiotic activity
WO2018112006A1 (en) * 2016-12-16 2018-06-21 Dupont Nutrition Biosciences Aps Bacillus-based components for inhibiting or delaying the growth of enterococcus spp. in animals
US11382938B2 (en) 2016-12-16 2022-07-12 Dupont Nutrition Biosciences Aps Bacillus-based components for inhibiting or delaying the growth of Enterococcus spp. in animals
WO2019040266A1 (en) * 2017-08-23 2019-02-28 Novozymes A/S Direct fed microbials for improving the general condition and health of fish
JP2021520197A (en) * 2018-04-23 2021-08-19 エボニック オペレーションズ ゲーエムベーハー Symbiotics composition
WO2019206820A1 (en) 2018-04-23 2019-10-31 Evonik Degussa Gmbh Synbiotic compositions
JP7407120B2 (en) 2018-04-23 2023-12-28 エボニック オペレーションズ ゲーエムベーハー synbiotic composition
RU2799354C2 (en) * 2018-04-23 2023-07-05 Эвоник Оперейшенс ГмбХ Synbiotic compositions
WO2019235952A1 (en) * 2018-06-04 2019-12-12 Lelyak Aleksandr Ivanovich Functional drinking water
WO2020011703A1 (en) 2018-07-11 2020-01-16 Evonik Operations Gmbh Composition comprising at least one microorganism and use thereof
CN112654256A (en) * 2018-09-11 2021-04-13 帝斯曼知识产权资产管理有限公司 Animal feed composition and use thereof
WO2020053274A1 (en) * 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
WO2020053271A1 (en) * 2018-09-11 2020-03-19 Dsm Ip Assets B.V. Animal feed composition and use thereof
US20220002667A1 (en) * 2018-11-12 2022-01-06 Dsm Ip Assets B.V. Bacillus sp. probiotic strains and mutations
WO2020225020A1 (en) 2019-05-03 2020-11-12 Evonik Operations Gmbh Feed compositions containing betaine salts
EP4317089A1 (en) * 2022-08-03 2024-02-07 Pruex Limited Treatment of animal waste
EP4342854A1 (en) * 2022-08-03 2024-03-27 Pruex Limited Treatment of animal waste
EP4382090A1 (en) * 2022-12-08 2024-06-12 Evonik Operations GmbH Cosmetical and pharmaceutical compositions containing bacillus strains or fermentation broths thereof
WO2024120910A1 (en) * 2022-12-08 2024-06-13 Evonik Operations Gmbh Cosmetical and pharmaceutical compositions containing bacillus strains or fermentation broths thereof

Also Published As

Publication number Publication date
JP6991162B2 (en) 2022-02-04
JP2019520064A (en) 2019-07-18
MX2018014476A (en) 2019-04-29
CN107446838A (en) 2017-12-08
EP3464558A1 (en) 2019-04-10
ZA201808509B (en) 2019-08-28
BR112018074616A2 (en) 2019-04-02

Similar Documents

Publication Publication Date Title
US11173184B2 (en) Bacillus subtilis strain with probiotic activity
WO2017207372A1 (en) Bacillus subtilis strain with probiotic activity
JP7104078B2 (en) Bacterial strain with probiotic activity
US20220117264A1 (en) Fermentation broths and their use
US11291695B2 (en) Bacillus subtilis strains improving animal performance parameters
EP3645750A1 (en) Bacillus pumilus
WO2017207371A9 (en) Bacillus licheniformis strain with probiotic activity
EP3447122A1 (en) Bacillus subtilis strain with probiotic activity
WO2019038153A1 (en) Bacillus subtilis strain with probiotic activity
JP2023123473A (en) Compositions containing bacillaene producing bacteria or preparations thereof
CN109423460A (en) Bacillus subtilis strains with probiotic activity
EP4090774A1 (en) Bacillus strains with the ability to degrade inorganic nitrogen compounds
WO2023156218A1 (en) Bacillota strains with improved outgrowth
US20190374585A1 (en) Feed additive formulation and methods of making and using the same
RU2804144C2 (en) Compositions containing bacillaene-producing bacteria or preparations thereof
TW201809264A (en) Bacillus licheniformis strain with probiotic activity
RU2810249C2 (en) Fermentation brothes and their applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17727530

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018562615

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018074616

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017727530

Country of ref document: EP

Effective date: 20190102

ENP Entry into the national phase

Ref document number: 112018074616

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181128